DK0772619T4 - Immunmodulatoriske oligonukleotider - Google Patents

Immunmodulatoriske oligonukleotider

Info

Publication number: DK0772619T4
Authority: DK; Denmark
Prior art keywords: immunomodulatory oligonucleotides; oligonucleotides; immunomodulatory; stabilised; contain
Prior art date: 1994-07-15

Application number

DK95911630.2T

Other languages

English (en)

Other versions

DK0772619T3 (da

Inventor

Arthur M Krieg

Dennis Klinman

Alfred D Steinberg

Original Assignee

Univ Iowa Res Found

Us Health

Coley Pharm Group Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-07-15

Filing date

1995-02-07

Publication date

2011-02-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23056334&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0772619(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-02-07 Application filed by Univ Iowa Res Found, Us Health, Coley Pharm Group Inc filed Critical Univ Iowa Res Found

2006-10-09 Publication of DK0772619T3 publication Critical patent/DK0772619T3/da

2011-02-21 Application granted granted Critical

2011-02-21 Publication of DK0772619T4 publication Critical patent/DK0772619T4/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/17—Immunomodulatory nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Virology (AREA)
Epidemiology (AREA)
Communicable Diseases (AREA)
Microbiology (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Tropical Medicine & Parasitology (AREA)
Neurology (AREA)
Dermatology (AREA)
Analytical Chemistry (AREA)
Neurosurgery (AREA)
Plant Pathology (AREA)
Mycology (AREA)
Pain & Pain Management (AREA)

DK95911630.2T 1994-07-15 1995-02-07 Immunmodulatoriske oligonukleotider DK0772619T4 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27635894A	1994-07-15	1994-07-15
PCT/US1995/001570 WO1996002555A1 (en)	1994-07-15	1995-02-07	Immunomodulatory oligonucleotides

Publications (2)

Publication Number	Publication Date
DK0772619T3 DK0772619T3 (da)	2006-10-09
DK0772619T4 true DK0772619T4 (da)	2011-02-21

Family

ID=23056334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95911630.2T DK0772619T4 (da)	1994-07-15	1995-02-07	Immunmodulatoriske oligonukleotider

Country Status (12)

Country	Link
US (1)	US6194388B1 (da)
EP (4)	EP0772619B2 (da)
JP (7)	JP3468773B2 (da)
AT (3)	ATE509102T1 (da)
AU (1)	AU713040B2 (da)
CA (2)	CA2560114A1 (da)
DE (2)	DE69535905D1 (da)
DK (1)	DK0772619T4 (da)
ES (3)	ES2267100T5 (da)
HK (3)	HK1043598A1 (da)
PT (1)	PT772619E (da)
WO (1)	WO1996002555A1 (da)

Families Citing this family (879)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5849719A (en)	1993-08-26	1998-12-15	The Regents Of The University Of California	Method for treating allergic lung disease
US6727230B1 (en) *	1994-03-25	2004-04-27	Coley Pharmaceutical Group, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) *	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6429199B1 (en) *	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
JP3468773B2 (ja) *	1994-07-15	2003-11-17	ザユニバーシティオブアイオワリサーチファウンデーション	免疫調節オリゴヌクレオチド
US6207646B1 (en) *	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US20030026782A1 (en) *	1995-02-07	2003-02-06	Arthur M. Krieg	Immunomodulatory oligonucleotides
US7935675B1 (en) *	1994-07-15	2011-05-03	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US7422902B1 (en) *	1995-06-07	2008-09-09	The University Of British Columbia	Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5981501A (en) *	1995-06-07	1999-11-09	Inex Pharmaceuticals Corp.	Methods for encapsulating plasmids in lipid bilayers
DE69737413T2 (de)	1996-01-04	2007-10-31	Novartis Vaccines and Diagnostics, Inc., Emeryville	Bakterioferritin aus helicobacter pylori
JP4359654B2 (ja) *	1996-01-30	2009-11-04	ザリージェンツオブザユニバーシティーオブカリフォルニア	抗原特異的免疫応答を生起させる遺伝子発現ベクターおよびその使用方法
FR2750704B1 (fr) *	1996-07-04	1998-09-25	Rhone Poulenc Rorer Sa	Procede de production d'adn therapeutique
US5856462A (en) *	1996-09-10	1999-01-05	Hybridon Incorporated	Oligonucleotides having modified CpG dinucleosides
ES2241042T3 (es)	1996-10-11	2005-10-16	The Regents Of The University Of California	Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
AU768178B2 (en) *	1996-10-11	2003-12-04	Regents Of The University Of California, The	Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0855184A1 (en)	1997-01-23	1998-07-29	Grayson B. Dr. Lipford	Pharmaceutical composition comprising a polynucleotide and an antigen especially for vaccination
EP1039935A4 (en) *	1997-02-28	2005-04-27	Univ Iowa Res Found	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
US6406705B1 (en) *	1997-03-10	2002-06-18	University Of Iowa Research Foundation	Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO1998040100A1 (en) *	1997-03-10	1998-09-17	Ottawa Civic Loeb Research Institute	USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
US6426334B1 (en)	1997-04-30	2002-07-30	Hybridon, Inc.	Oligonucleotide mediated specific cytokine induction and reduction of tumor growth in a mammal
US20030104044A1 (en) *	1997-05-14	2003-06-05	Semple Sean C.	Compositions for stimulating cytokine secretion and inducing an immune response
DE69841002D1 (de)	1997-05-14	2009-09-03	Univ British Columbia	Hochwirksame verkapselung von nukleinsäuren in lipidvesikeln
AU7589398A (en) *	1997-05-19	1998-12-11	Merck & Co., Inc.	Oligonucleotide adjuvant
US6339068B1 (en)	1997-05-20	2002-01-15	University Of Iowa Research Foundation	Vectors and methods for immunization or therapeutic protocols
ATE432348T1 (de)	1997-06-06	2009-06-15	Univ California	Inhibitoren von immunstimulatorischen dna sequenz aktivität
EP1374894A3 (en) *	1997-06-06	2004-09-22	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20040006034A1 (en) *	1998-06-05	2004-01-08	Eyal Raz	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US6589940B1 (en)	1997-06-06	2003-07-08	Dynavax Technologies Corporation	Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
AU757175B2 (en) *	1997-09-05	2003-02-06	Regents Of The University Of California, The	Use of immunostimulatory oligonucleotides for preventing or reducing antigen-stimulated, granulocyte-mediated inflammation
GB9724531D0 (en)	1997-11-19	1998-01-21	Smithkline Biolog	Novel compounds
CA2319309C (en)	1998-02-05	2010-08-10	Smithkline Beecham Biologicals S.A.	Tumor-associated antigen derivatives from the mage family, and nucleic acid sequences encoding them, used for the preparation of fusion proteins and of compositions for vaccination
US20020147143A1 (en)	1998-03-18	2002-10-10	Corixa Corporation	Compositions and methods for the therapy and diagnosis of lung cancer
CA2323929C (en) *	1998-04-03	2004-03-09	University Of Iowa Research Foundation	Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
EP1069910A1 (en) *	1998-04-09	2001-01-24	GlaxoSmithKline Biologicals S.A.	Adjuvant compositions
GB9808866D0 (en)	1998-04-24	1998-06-24	Smithkline Beecham Biolog	Novel compounds
JP2002513763A (ja) *	1998-05-06	2002-05-14	ユニバーシティオブアイオワリサーチファウンデーション	Ｃｐｇオリゴヌクレオチドを使用して寄生生物感染および関連する疾患を予防および処置するための方法
NZ508650A (en) *	1998-05-14	2003-05-30	Coley Pharm Gmbh	Regulating hematopoiesis using unmethylated C and G CpG-oligonucleotides with a phosphorothioate modification
DK1079824T3 (da)	1998-05-19	2011-11-21	Res Dev Foundation	Triterpen-sammensætninger og fremgangsmåder til anvendelse deraf
ES2272069T3 (es) *	1998-05-22	2007-04-16	Ottawa Health Research Institute	Metodos y productos para inducir inmunidad en mucosas.
US6881561B1 (en)	1998-05-27	2005-04-19	Cheil Jedang Corporation	Endonuclease of immune cell, process for producing the same and immune adjuvant using the same
KR19990086271A (ko) *	1998-05-27	1999-12-15	손경식	면역세포의 신규한 엔도뉴클레아제 및 이를 사용한 면역보조제
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030022854A1 (en) *	1998-06-25	2003-01-30	Dow Steven W.	Vaccines using nucleic acid-lipid complexes
US6693086B1 (en) *	1998-06-25	2004-02-17	National Jewish Medical And Research Center	Systemic immune activation method using nucleic acid-lipid complexes
US20040247662A1 (en) *	1998-06-25	2004-12-09	Dow Steven W.	Systemic immune activation method using nucleic acid-lipid complexes
WO2000006588A1 (en) *	1998-07-27	2000-02-10	University Of Iowa Research Foundation	STEREOISOMERS OF CpG OLIGONUCLEOTIDES AND RELATED METHODS
EP1103564B1 (en)	1998-07-31	2009-01-07	International Institute of Cancer Immunology, Inc.	Cancer antigens based on tumor suppressor gene wt1 product
CN1348463A (zh)	1998-08-07	2002-05-08	华盛顿大学	免疫学单纯疱疹病毒抗原及其使用方法
DE69929444T2 (de) *	1998-08-10	2006-09-28	Antigenics Inc., Woburn	Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
JP2002524473A (ja) *	1998-09-09	2002-08-06	ジエンザイムコーポレイション	プラスミドベクターのメチル化
US6692752B1 (en)	1999-09-08	2004-02-17	Smithkline Beecham Biologicals S.A.	Methods of treating human females susceptible to HSV infection
FR2783170B1 (fr) *	1998-09-11	2004-07-16	Pasteur Merieux Serums Vacc	Emulsion immunostimulante
WO2000016804A1 (en) *	1998-09-18	2000-03-30	Dynavax Technologies Corporation	METHODS OF TREATING IgE-ASSOCIATED DISORDERS AND COMPOSITIONS FOR USE THEREIN
US20030235557A1 (en)	1998-09-30	2003-12-25	Corixa Corporation	Compositions and methods for WT1 specific immunotherapy
JP2002526425A (ja) *	1998-10-05	2002-08-20	ザリージェンツオブザユニバーシティオブカリフォルニア	粘膜免疫を刺激するための方法およびアジュバント
PL201482B1 (pl)	1998-10-16	2009-04-30	Smithkline Beecham Biolog	Sposoby wytwarzania kompozycji szczepionki oraz kompozycja szczepionki
US6706270B1 (en)	1998-12-08	2004-03-16	Smithkline Beecham Biologicals S.A.	Compounds
IL143531A0 (en)	1998-12-08	2002-04-21	Corixa Corp	Polypeptides containing an antigenic portion of a chlamydia antigen, dna sequences encoding said polypeptides and pharmaceutical compositions and vaccines containing the same
US20020119158A1 (en)	1998-12-17	2002-08-29	Corixa Corporation	Compositions and methods for the therapy and diagnosis of ovarian cancer
US6579973B1 (en)	1998-12-28	2003-06-17	Corixa Corporation	Compositions for the treatment and diagnosis of breast cancer and methods for their use
US7198920B1 (en)	1999-01-29	2007-04-03	Corika Corporation	HER-2/neu fusion proteins
WO2000045849A2 (en) *	1999-02-05	2000-08-10	Genzyme Corporation	Use of cationic lipids to generate anti-tumor immunity
NZ513935A (en)	1999-02-17	2004-02-27	Csl Ltd	Immunogenic complexes and methods relating thereto
EP1574210B1 (en)	1999-02-26	2016-04-06	Novartis Vaccines and Diagnostics, Inc.	Microemulsions with adsorbed macromolecules
ATE279943T1 (de)	1999-02-26	2004-11-15	Chiron Srl	Verbesserung der bakterizidaktivität von neisseria antigenen mit cg enthaltende oligonukleotiden
EP2270169A3 (en)	1999-03-12	2011-06-15	GlaxoSmithKline Biologicals SA	Neisseria meningitidis antigenic polypeptides, corresponding polynucleotides and protective antibodies
FR2790955B1 (fr) *	1999-03-19	2003-01-17	Assist Publ Hopitaux De Paris	Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
GB9909077D0 (en)	1999-04-20	1999-06-16	Smithkline Beecham Biolog	Novel compositions
DK1163000T3 (da)	1999-03-19	2008-04-28	Glaxosmithkline Biolog Sa	Vacciner imod antigener fra bakterier
JP2000262247A (ja) *	1999-03-19	2000-09-26	Asama Kasei Kk	免疫調節剤、免疫調節食品および免疫調節飼料
EP1169347B1 (en)	1999-04-02	2008-07-02	Corixa Corporation	Compounds and methods for therapy and diagnosis of lung cancer
US6977245B2 (en)	1999-04-12	2005-12-20	The United States Of America As Represented By The Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
WO2000061151A2 (en)	1999-04-12	2000-10-19	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Oligodeoxynucleotide and its use to induce an immune response
DK1187629T3 (da)	1999-04-19	2005-01-17	Glaxosmithkline Biolog Sa	Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
US6558670B1 (en)	1999-04-19	2003-05-06	Smithkline Beechman Biologicals S.A.	Vaccine adjuvants
DE60013591T2 (de) *	1999-04-29	2005-02-03	Coley Pharmaceutical Gmbh	Screening nach modulatoren der funktion von immunstimulatorischer dna
GB9915204D0 (en) *	1999-06-29	1999-09-01	Smithkline Beecham Biolog	Vaccine
CA2376992A1 (en) *	1999-06-29	2001-01-04	Smithkline Beecham Biologicals S.A.	Use of cpg as an adjuvant for hiv vaccine
US6514948B1 (en)	1999-07-02	2003-02-04	The Regents Of The University Of California	Method for enhancing an immune response
FR2795963A1 (fr) *	1999-07-08	2001-01-12	Pasteur Merieux Serums Vacc	Polynucleotide immunostimulant
SK782002A3 (en) *	1999-07-21	2003-08-05	Lexigen Pharm Corp	FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB9918319D0 (en)	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
US20050226890A1 (en) *	1999-08-12	2005-10-13	Cohen David I	Tat-based vaccine compositions and methods of making and using same
US7479285B1 (en)	1999-08-19	2009-01-20	Dynavax Technologies Corporation	Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
DE60036950T2 (de) *	1999-08-27	2008-08-07	Inex Pharmaceuticals Corp., Burnaby	Zusammensetzungen zur stimulation der zytokin sekretion und zur induktion einer immunantwort
SK287400B6 (sk)	1999-09-25	2010-08-09	University Of Iowa Research Foundation	Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
US6949520B1 (en) *	1999-09-27	2005-09-27	Coley Pharmaceutical Group, Inc.	Methods related to immunostimulatory nucleic acid-induced interferon
ES2306670T3 (es)	1999-10-22	2008-11-16	Sanofi Pasteur Limited	Procedimiento de induccion y/o intensificacion de la respuesta inmunitaria frente a antigenos tumorales.
US7223398B1 (en)	1999-11-15	2007-05-29	Dynavax Technologies Corporation	Immunomodulatory compositions containing an immunostimulatory sequence linked to antigen and methods of use thereof
AU2593701A (en) *	1999-12-21	2001-07-03	Regents Of The University Of California, The	Method for preventing an anaphylactic reaction
DE60131430T2 (de)	2000-01-14	2008-10-16	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Oligodeoxynukleotide und ihre verwendung zur induktion einer immunreaktion
AT409085B (de) *	2000-01-28	2002-05-27	Cistem Biotechnologies Gmbh	Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
US6552006B2 (en)	2000-01-31	2003-04-22	The Regents Of The University Of California	Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
US7585847B2 (en)	2000-02-03	2009-09-08	Coley Pharmaceutical Group, Inc.	Immunostimulatory nucleic acids for the treatment of asthma and allergy
FR2805264B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
FR2805265B1 (fr) *	2000-02-18	2002-04-12	Aventis Pasteur	Oligonucleotides immunostimulants
AU4175101A (en) *	2000-02-23	2001-09-03	Univ California	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
PL209127B1 (pl) *	2000-02-23	2011-07-29	Smithkline Beecham Biolog	Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
US20030130217A1 (en) *	2000-02-23	2003-07-10	Eyal Raz	Method for treating inflammatory bowel disease and other forms of gastrointestinal inflammation
US20040002068A1 (en)	2000-03-01	2004-01-01	Corixa Corporation	Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
US20040131628A1 (en) *	2000-03-08	2004-07-08	Bratzler Robert L.	Nucleic acids for the treatment of disorders associated with microorganisms
US20020098199A1 (en)	2000-03-10	2002-07-25	Gary Van Nest	Methods of suppressing hepatitis virus infection using immunomodulatory polynucleotide sequences
US20010046967A1 (en)	2000-03-10	2001-11-29	Gary Van Nest	Methods of preventing and treating respiratory viral infection using immunomodulatory polynucleotide
US7129222B2 (en)	2000-03-10	2006-10-31	Dynavax Technologies Corporation	Immunomodulatory formulations and methods for use thereof
US7157437B2 (en)	2000-03-10	2007-01-02	Dynavax Technologies Corporation	Methods of ameliorating symptoms of herpes infection using immunomodulatory polynucleotide sequences
US20030129251A1 (en)	2000-03-10	2003-07-10	Gary Van Nest	Biodegradable immunomodulatory formulations and methods for use thereof
EP1278550A4 (en) *	2000-04-07	2004-05-12	Univ California	SYNERGISTIC IMPROVEMENTS OF POLYNUCLEOTIDE VACCINE
DE60133190T2 (de)	2000-04-21	2009-04-02	CORIXA CORP., Wilmington	Verbindungen und verfahren zur behandlung und diagnose von chlamydia-infektionen
ATE346925T1 (de)	2000-05-10	2006-12-15	Sanofi Pasteur Ltd	Durch mage minigene kodierte immunogene polypeptide und ihre verwendungen
BR0110975A (pt)	2000-05-19	2004-03-23	Corixa Corp	Tratamento profilático e terapêutico de doenças infecciosas ou outras doenças com compostos à base de mono- e disacarìdeos
EP1542732B1 (en)	2000-06-20	2009-09-16	Corixa Corporation	Fusion proteins of mycobacterium tuberculosis
ATE440618T1 (de)	2000-06-22	2009-09-15	Univ Iowa Res Found	Kombination von cpg und antikírpern gegen cd19, cd20,cd22 oder cd40 zur prävention oder behandlung von krebs.
AR029540A1 (es)	2000-06-28	2003-07-02	Corixa Corp	COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
GB0108364D0 (en)	2001-04-03	2001-05-23	Glaxosmithkline Biolog Sa	Vaccine composition
KR100898845B1 (ko)	2000-06-29	2009-05-21	글락소스미스클라인 바이오로지칼즈 에스.에이.	다가 백신 조성물
US7229623B1 (en)	2000-08-03	2007-06-12	Corixa Corporation	Her-2/neu fusion proteins
KR100917101B1 (ko) *	2000-08-04	2009-09-15	도요 보세키 가부시키가이샤	플렉시블 금속적층체 및 그 제조방법
US20080044435A1 (en) *	2004-03-16	2008-02-21	Cohen David I	Tat-Based Tolerogen Compositions and Methods of Making and Using Same
UA79735C2 (uk)	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
WO2002011761A2 (en) *	2000-08-10	2002-02-14	Henry M. Jackson Foundation For The Advancement Of Military Medicine	Vaccine against rsv
WO2002016549A2 (en) *	2000-08-25	2002-02-28	Yeda Research And Development Co. Ltd.	METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
US6943240B2 (en)	2000-09-15	2005-09-13	Coley Pharmaceuticals Gmbh	Nucleic acids for high throughput screening of CpG-based immuno-agonist/antagonist
GB0022742D0 (en)	2000-09-15	2000-11-01	Smithkline Beecham Biolog	Vaccine
PT2266603E (pt)	2000-10-18	2012-11-02	Glaxosmithkline Biolog Sa	Vacinas tumorais
ES2330083T3 (es)	2000-10-27	2009-12-04	Novartis Vaccines And Diagnostics S.R.L.	Acidos nucleicos y proteinas de estreptococos de los grupos a y b.
US6677347B2 (en) *	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
JP2008531580A (ja) *	2000-12-08	2008-08-14	スリーエムイノベイティブプロパティズカンパニー	免疫応答修飾因子の標的化送達のための組成物および方法
ES2307568T3 (es) *	2000-12-08	2008-12-01	Coley Pharmaceutical Gmbh	Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
US20030049266A1 (en)	2000-12-27	2003-03-13	Fearon Karen L.	Immunomodulatory polynucleotides and methods of using the same
WO2002055090A1 (fr) *	2001-01-12	2002-07-18	Amato Pharmaceutical Products,Ltd.	Agents preventifs d'infections microbiennes
CA2434574A1 (en) *	2001-01-12	2002-07-18	Amato Pharmaceutical Products, Ltd.	An antiallergic agent
US7128911B2 (en)	2001-01-19	2006-10-31	Cytos Biotechnology Ag	Antigen arrays for treatment of bone disease
US20040116520A1 (en) *	2001-01-24	2004-06-17	Amato Pharmaceutical Products, Ltd.	Anti-stress agents
DE10105234A1 (de)	2001-02-02	2002-08-29	Schoeller Textil Ag Sevelen	Textile Fläche
GB0103171D0 (en)	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
GB0105360D0 (en) *	2001-03-03	2001-04-18	Glaxo Group Ltd	Chimaeric immunogens
US20040097703A1 (en)	2001-03-22	2004-05-20	Haruo Sugiyama	Wt1 modified peptide
US20030050268A1 (en) *	2001-03-29	2003-03-13	Krieg Arthur M.	Immunostimulatory nucleic acid for treatment of non-allergic inflammatory diseases
JP2005504513A (ja)	2001-05-09	2005-02-17	コリクサコーポレイション	前立腺癌の治療及び診断のための組成物及び方法
CN1526016A (zh)	2001-05-21	2004-09-01	��ɷ�	稳定核酸的方法
US6818787B2 (en) *	2001-06-11	2004-11-16	Xenoport, Inc.	Prodrugs of GABA analogs, compositions and uses thereof
GB0115176D0 (en)	2001-06-20	2001-08-15	Chiron Spa	Capular polysaccharide solubilisation and combination vaccines
DK2423335T3 (da)	2001-06-21	2014-08-18	Dynavax Tech Corp	Kimæriske immunmodulatoriske forbindelser og fremgangsmåder til anvendelse deraf
US7785610B2 (en) *	2001-06-21	2010-08-31	Dynavax Technologies Corporation	Chimeric immunomodulatory compounds and methods of using the same—III
CZ20033515A3 (cs) *	2001-06-29	2005-01-12	Chiron Corporation	Kompozice vakcíny HCV E1E2
US20030108565A1 (en)	2001-07-10	2003-06-12	Johnson Mark E.	Compositions and methods for delivery of proteins and adjuvants encapsulated in microspheres
GB0118249D0 (en)	2001-07-26	2001-09-19	Chiron Spa	Histidine vaccines
GB0121591D0 (en)	2001-09-06	2001-10-24	Chiron Spa	Hybrid and tandem expression of neisserial proteins
US7666674B2 (en)	2001-07-27	2010-02-23	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of sterically stabilized cationic liposomes to efficiently deliver CPG oligonucleotides in vivo
AU2002318944A1 (en) *	2001-08-01	2003-02-17	Coley Pharmaceutical Gmbh	Methods and compositions relating to plasmacytoid dendritic cells
WO2003025119A2 (en) *	2001-08-03	2003-03-27	Medarex, Inc.	Compositions comprising immunostimulatory oligonucleotides and uses thereof to enhance fc receptor-mediated immunotherapies
AU2002326561B2 (en) *	2001-08-07	2008-04-03	Dynavax Technologies Corporation	Immunomodulatory compositions, formulations, and methods for use thereof
WO2003020884A2 (en) *	2001-08-14	2003-03-13	The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services	Method for rapid generation of mature dendritic cells
US7361352B2 (en)	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
IL160157A0 (en) *	2001-08-17	2004-07-25	Coley Pharm Group Inc	Combination motif immune stimulation oligonucleotides with improved activity
WO2003018611A2 (en)	2001-08-24	2003-03-06	University Of Victoria Innovation And Development Corporation	Proaerolysin containing protease activation sequences and methods of use for treatment of prostate cancer
WO2003020889A2 (en) *	2001-08-30	2003-03-13	3M Innovative Properties Company	Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules
KR20040053122A (ko) *	2001-09-07	2004-06-23	더 트러스티즈 오브 보스톤 유니버시티	면역 복합체 관련 질환의 치료 방법 및 이를 위한 조성물
ES2335979T3 (es)	2001-09-14	2010-04-07	Cytos Biotechnology Ag	Empaquetamiento de cpg inmunoestimuladores en particulas similares a virus: metodo de preparacion y su uso.
WO2003024480A2 (en) *	2001-09-14	2003-03-27	Cytos Biotechnology Ag	In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
PL207168B1 (pl)	2001-09-20	2010-11-30	Glaxo Group Ltd	Sekwencja nukleotydowa, wektor, białko, środek farmaceutyczny, urządzenie do podawania śródskórnego, zastosowanie sekwencji nukleotydowej i sposób wytwarzania nukleotydu
WO2003027313A2 (en)	2001-09-24	2003-04-03	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20030119774A1 (en) *	2001-09-25	2003-06-26	Marianna Foldvari	Compositions and methods for stimulating an immune response
JPWO2003028758A1 (ja) *	2001-09-28	2005-01-13	治夫杉山	抗原特異的ｔ細胞の誘導方法
US8735357B2 (en)	2001-09-28	2014-05-27	International Institute Of Cancer Immunology, Inc.	Method of inducing antigen-specific T cells
AR045702A1 (es)	2001-10-03	2005-11-09	Chiron Corp	Composiciones de adyuvantes.
IL160837A0 (en) *	2001-10-05	2004-08-31	Coley Pharm Gmbh	Toll-like receptor 3 signaling agonists and antagonists
US20030139364A1 (en) *	2001-10-12	2003-07-24	University Of Iowa Research Foundation	Methods and products for enhancing immune responses using imidazoquinoline compounds
TW200303759A (en) *	2001-11-27	2003-09-16	Schering Corp	Methods for treating cancer
EP1450821A1 (en) *	2001-12-07	2004-09-01	Intercell AG	Immunostimulatory oligodeoxynucleotides
EP1465634B1 (en)	2001-12-12	2014-10-22	The Government of the United States of America, as represented by the Secretary Department of Health and Human Services	Methods for using adenosine receptor inhibitors to enhance immune response and inflammation
DK1581119T3 (da)	2001-12-17	2013-05-13	Corixa Corp	Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
AU2002366710A1 (en)	2001-12-20	2003-07-09	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
US8466116B2 (en)	2001-12-20	2013-06-18	The Unites States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Use of CpG oligodeoxynucleotides to induce epithelial cell growth
AU2002357359B2 (en) *	2001-12-21	2009-01-08	Csl Limited	Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
US20040034223A1 (en) *	2002-02-07	2004-02-19	Covalent Partners, Llc.	Amphiphilic molecular modules and constructs based thereon
WO2003067286A2 (en) *	2002-02-07	2003-08-14	Covalent Partners, Llc	Nanofilm and membrane compositions
US8088388B2 (en) *	2002-02-14	2012-01-03	United Biomedical, Inc.	Stabilized synthetic immunogen delivery system
US7501134B2 (en)	2002-02-20	2009-03-10	Novartis Vaccines And Diagnostics, Inc.	Microparticles with adsorbed polypeptide-containing molecules
US7351413B2 (en)	2002-02-21	2008-04-01	Lorantis, Limited	Stabilized HBc chimer particles as immunogens for chronic hepatitis
US20050222060A1 (en) *	2002-03-15	2005-10-06	Bot Adrian L	Compositions and methods to initiate or enhance antibody and major-histocompatibility class I or class II-restricted t cell responses by using immunomodulatory, non-coding rna motifs
US20070037769A1 (en) *	2003-03-14	2007-02-15	Multicell Immunotherapeutics, Inc.	Compositions and methods to treat and control tumors by loading antigen presenting cells
EP2258712A3 (en)	2002-03-15	2011-05-04	Multicell Immunotherapeutics, Inc.	Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
EP1499187B1 (en) *	2002-04-04	2015-06-17	Zoetis Belgium S.A.	Immunostimulatory g,u-containing oligoribonucleotides
US20030224013A1 (en) *	2002-04-19	2003-12-04	Cole Garry T.	Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
US20040013649A1 (en) *	2002-05-10	2004-01-22	Inex Pharmaceuticals Corporation	Cancer vaccines and methods of using the same
US20040009943A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Pathogen vaccines and methods for using the same
EP1503793A2 (en) *	2002-05-10	2005-02-09	Inex Pharmaceuticals Corp.	Cancer vaccines and methods of using the same
US20040009944A1 (en) *	2002-05-10	2004-01-15	Inex Pharmaceuticals Corporation	Methylated immunostimulatory oligonucleotides and methods of using the same
KR100456681B1 (ko) *	2002-05-22	2004-11-10	주식회사 대웅	박테리아의 염색체 ｄｎａ 파쇄물과 비독성리포폴리사카라이드를 포함하는 면역강화 및 조절 조성물
CA2388049A1 (en)	2002-05-30	2003-11-30	Immunotech S.A.	Immunostimulatory oligonucleotides and uses thereof
WO2003103586A2 (en) *	2002-06-05	2003-12-18	Coley Pharmaceutical Group, Inc.	Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
SE0201701D0 (sv) *	2002-06-05	2002-06-05	Gotovax Ab	Treatment of epithelial tumors and infections
PL375306A1 (en) *	2002-06-20	2005-11-28	Cytos Biotechnology Ag	Packaged virus-like particles for use as adjuvants: method of preparation and use
AU2002368055B2 (en)	2002-06-28	2008-09-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating autoimmune diseases with interferon-beta and IL-2R antagonist
US7576066B2 (en) *	2002-07-03	2009-08-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
DE10229872A1 (de)	2002-07-03	2004-01-29	Curevac Gmbh	Immunstimulation durch chemisch modifizierte RNA
US7605138B2 (en) *	2002-07-03	2009-10-20	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US20040053880A1 (en) *	2002-07-03	2004-03-18	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7807803B2 (en)	2002-07-03	2010-10-05	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
US7569553B2 (en)	2002-07-03	2009-08-04	Coley Pharmaceutical Group, Inc.	Nucleic acid compositions for stimulating immune responses
AU2003255969A1 (en) *	2002-07-17	2004-02-02	Coley Pharmaceutical Gmbh	Use of cpg nucleic acids in prion-disease
ATE414176T1 (de)	2002-07-18	2008-11-15	Univ Washington	Schnelle, effiziente reinigung von hsv- spezifischen t-lymphozyten und damit identifizierte hsv-antigene
CN1650012A (zh)	2002-07-24	2005-08-03	英特塞尔股份公司	来自致病病毒的备选阅读框所编码的抗原
AU2003263963A1 (en)	2002-08-01	2004-02-23	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
CA2489030A1 (en)	2002-08-02	2004-02-19	Glaxosmithkline Biologicals S.A.	Vaccine composition comprising transferrin binding protein and hsf from gram negative bacteria
WO2004032829A2 (en)	2002-08-15	2004-04-22	3M Innovative Properties Company	Immunostimulatory compositions and methods of stimulating an immune response
AR040996A1 (es) *	2002-08-19	2005-04-27	Coley Pharm Group Inc	Acidos nucleicos inmunoestimuladores
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
EP1537418A2 (en)	2002-09-13	2005-06-08	Intercell AG	Method for isolating hepatitis c virus peptides
US20040106741A1 (en) *	2002-09-17	2004-06-03	Kriesel Joshua W.	Nanofilm compositions with polymeric components
US8263091B2 (en) *	2002-09-18	2012-09-11	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating and preventing infections in immunocompromised subjects with immunostimulatory CpG oligonucleotides
AU2003268737A1 (en) *	2002-10-02	2004-04-23	Mochida Pharmaceutical Co., Ltd.	Novel method of constructing monoclonal antibody
US8043622B2 (en)	2002-10-08	2011-10-25	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
CN102174533A (zh)	2002-10-15	2011-09-07	英特塞尔股份公司	编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
PL376792A1 (pl)	2002-10-23	2006-01-09	Glaxosmithkline Biologicals S.A.	Sposoby szczepienia przeciwko malarii
AU2003301526A1 (en) *	2002-10-25	2004-05-13	University Of Connecticut Health Center	Immunotherapy of cancer through controlled cell lysis
EA008777B1 (ru) *	2002-10-29	2007-08-31	Коли Фармасьютикал Груп, Лтд.	Способы и продукты, относящиеся к лечению и предупреждению инфекции вируса гепатита c
WO2004098491A2 (en) *	2002-11-01	2004-11-18	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	METHOD OF PREVENTING INFECTIONS FROM BIOTERRORISM AGENTS WITH IMMUNOSTIMULATORY CpG OLIGONUCLEOTIDES
US7491509B2 (en)	2003-02-03	2009-02-17	Fraunhofer Usa, Inc.	System for expression of genes in plants
ATE466875T1 (de)	2002-11-15	2010-05-15	Novartis Vaccines & Diagnostic	Unerwartete oberflächenproteine in neisseria meningitidis
DE60333786D1 (de) *	2002-11-21	2010-09-23	Univ R	Verfahren und immunmodulierende nukleinsäurezusammensetzungen zur vorbeugung und behandlungvon erkrankungen
GB0227346D0 (en)	2002-11-22	2002-12-31	Chiron Spa	741
WO2004052293A2 (en) *	2002-12-11	2004-06-24	Hawaii Biotech, Inc.	Recombinant vaccine against flavivirus infection
US7956043B2 (en)	2002-12-11	2011-06-07	Coley Pharmaceutical Group, Inc.	5′ CpG nucleic acids and methods of use
US20050287170A1 (en) *	2002-12-11	2005-12-29	Hawaii Biotech, Inc.	Subunit vaccine against West Nile viral infection
KR100525321B1 (ko) *	2002-12-13	2005-11-02	안웅식	파필로마바이러스 항원 단백질 및ＣｐＧ-올리고데옥시뉴클레오타이드를 포함하는파필로마바이러스 유발 질환의 예방 또는 치료용 약제학적조성물
CA2508985A1 (en) *	2002-12-23	2004-07-15	Dynavax Technologies Corporation	Branched immunomodulatory compounds and methods of using the same
US8158768B2 (en)	2002-12-23	2012-04-17	Dynavax Technologies Corporation	Immunostimulatory sequence oligonucleotides and methods of using the same
SI1575977T1 (sl)	2002-12-23	2010-01-29	Dynavax Tech Corp	Imunostimulirni sekvenčni polinukleotidi in postopki za njihovo uporabo
JP2006520746A (ja)	2002-12-27	2006-09-14	カイロンコーポレイション	リン脂質を含む免疫原性組成物
WO2004060319A2 (en)	2002-12-30	2004-07-22	3M Innovative Properties Company	Immunostimulatory combinations
CN101080234A (zh)	2003-01-06	2007-11-28	科里克萨有限公司	一些氨烷基氨基葡糖苷磷酸酯化合物和它们的用途
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
US7375180B2 (en) *	2003-02-13	2008-05-20	3M Innovative Properties Company	Methods and compositions related to IRM compounds and Toll-like receptor 8
JP4976848B2 (ja)	2003-02-20	2012-07-18	ユニバーシティーオブコネティカットヘルスセンター	アルファ（２）マクログロブリン−抗原分子複合体を用いる癌および感染性疾患の治療のための方法および組成物
GB2398783A (en)	2003-02-26	2004-09-01	Antonio Lanzavecchia	A method for producing immortalised human B memory lymphocytes
US7485432B2 (en) *	2003-02-27	2009-02-03	3M Innovative Properties Company	Selective modulation of TLR-mediated biological activity
JP2006519866A (ja)	2003-03-04	2006-08-31	スリーエムイノベイティブプロパティズカンパニー	Ｕｖ誘発性の表皮の新形成の予防的治療
AU2004218284B2 (en)	2003-03-04	2009-07-23	Intercell Ag	Streptococcus pyogenes antigens
US7179253B2 (en)	2003-03-13	2007-02-20	3M Innovative Properties Company	Method of tattoo removal
ATE556711T1 (de) *	2003-03-13	2012-05-15	3M Innovative Properties Co	Verfahren zur verbesserung der hautqualität
JP4676426B2 (ja)	2003-03-24	2011-04-27	インターツェル・アクチェンゲゼルシャフト	改良型ワクチン
US20040192585A1 (en)	2003-03-25	2004-09-30	3M Innovative Properties Company	Treatment for basal cell carcinoma
CA2517839A1 (en) *	2003-03-26	2004-10-07	Martin F. Bachmann	Melan-a peptide analogue-virus-like-particle conjugates
US20060172959A1 (en) *	2003-03-26	2006-08-03	Dan Smith	Selected rna motifs to include cell death and/or apoptosis
US7537767B2 (en)	2003-03-26	2009-05-26	Cytis Biotechnology Ag	Melan-A- carrier conjugates
EP2182065A3 (en)	2003-03-31	2010-09-15	Intercell AG	Staphylococcus epidermidis antigens
CA2521050A1 (en) *	2003-04-02	2004-10-14	Coley Pharmaceutical Group, Ltd.	Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US20040265351A1 (en) *	2003-04-10	2004-12-30	Miller Richard L.	Methods and compositions for enhancing immune response
WO2004108072A2 (en) *	2003-04-10	2004-12-16	3M Innovative Properties Company	Delivery of immune response modifier compounds using metal-containing particulate support materials
SE0301109D0 (sv) *	2003-04-14	2003-04-14	Mallen Huang	Nucleotide vaccine composition
EP2311987A1 (en)	2003-04-15	2011-04-20	Intercell AG	S. pneumoniae antigens
WO2004096144A2 (en) *	2003-04-28	2004-11-11	3M Innovative Properties Company	Compositions and methods for induction of opioid receptors
US7438912B2 (en)	2003-05-07	2008-10-21	Intercell Ag	S.agalactiae antigens I + II
KR100872472B1 (ko) *	2003-05-15	2008-12-05	도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬	면역자극제
ES2427641T3 (es)	2003-05-22	2013-10-31	Ibio, Inc.	Molécula vehículo recombinante para la expresión, el suministro y la purificación de polipéptidos diana
US20080175856A1 (en)	2003-05-30	2008-07-24	Intercell Ag	Enterococcus Antigens
ATE437633T2 (de)	2003-06-02	2009-08-15	Novartis Vaccines & Diagnostic	Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
CA2528067C (en)	2003-06-05	2015-08-04	The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Poly-gamma-glutamic acid conjugates for eliciting immune responses directed against bacilli
EP1635846A4 (en) *	2003-06-20	2009-01-28	Coley Pharm Gmbh	SMALL MOLECULAR TLR (TOLL-LIKE RECEPTOR) ANTAGONISTS
JP2009513532A (ja) *	2003-07-10	2009-04-02	サイトスバイオテクノロジーアーゲー	パッケージ化ウイルス様粒子
US20050013812A1 (en) *	2003-07-14	2005-01-20	Dow Steven W.	Vaccines using pattern recognition receptor-ligand:lipid complexes
WO2005016275A2 (en) *	2003-08-05	2005-02-24	3M Innovative Properties Company	Formulations containing an immune response modifier
WO2005018551A2 (en) *	2003-08-12	2005-03-03	3M Innovative Properties Company	Oxime substituted imidazo-containing compounds
US20060035242A1 (en)	2004-08-13	2006-02-16	Michelitsch Melissa D	Prion-specific peptide reagents
WO2005018574A2 (en) *	2003-08-25	2005-03-03	3M Innovative Properties Company	Immunostimulatory combinations and treatments
CA2536136C (en) *	2003-08-27	2012-10-30	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted imidazoquinolines
CA2536578A1 (en) *	2003-09-02	2005-03-10	3M Innovative Properties Company	Methods related to the treatment of mucosal associated conditions
WO2005023190A2 (en) *	2003-09-05	2005-03-17	3M Innovative Properties Company	Treatment for cd5+ b cell lymphoma
JP2007505147A (ja)	2003-09-12	2007-03-08	アンティジェニクスインコーポレーテッド	単純ヘルペスウイルス感染の治療および予防用ワクチン
CA2536139A1 (en) *	2003-09-25	2005-04-07	Coley Pharmaceutical Group, Inc.	Nucleic acid-lipophilic conjugates
CA2539715C (en)	2003-10-02	2015-02-24	Glaxosmithkline Biologicals S.A.	Pertussis antigens and use thereof in vaccination
US20090075980A1 (en) *	2003-10-03	2009-03-19	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and Analogs Thereof
US7544697B2 (en) *	2003-10-03	2009-06-09	Coley Pharmaceutical Group, Inc.	Pyrazolopyridines and analogs thereof
US8871782B2 (en) *	2003-10-03	2014-10-28	3M Innovative Properties Company	Alkoxy substituted imidazoquinolines
CA2542099A1 (en) *	2003-10-11	2005-04-21	Inex Pharmaceuticals Corporation	Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity
NZ546475A (en) *	2003-10-30	2008-08-29	Coley Pharm Gmbh	C-Class oligonucleotide analogs with enhanced immunostimulatory potency
US20050096259A1 (en) *	2003-10-31	2005-05-05	3M Innovative Properties Company	Neutrophil activation by immune response modifier compounds
US20050239733A1 (en) *	2003-10-31	2005-10-27	Coley Pharmaceutical Gmbh	Sequence requirements for inhibitory oligonucleotides
US20050100983A1 (en) *	2003-11-06	2005-05-12	Coley Pharmaceutical Gmbh	Cell-free methods for identifying compounds that affect toll-like receptor 9 (TLR9) signaling
EP1685129A4 (en)	2003-11-14	2008-10-22	3M Innovative Properties Co	OXIMSUBSTITUTED IMIDAZORING CONNECTIONS
CA2545825A1 (en) *	2003-11-14	2005-06-02	3M Innovative Properties Company	Hydroxylamine substituted imidazo ring compounds
MY161812A (en) *	2003-11-25	2017-05-15	3M Innovative Properties Co	Substituted imidazo ring systems and methods
US20050287118A1 (en) *	2003-11-26	2005-12-29	Epitomics, Inc.	Bacterial plasmid with immunological adjuvant function and uses thereof
US20050277127A1 (en) *	2003-11-26	2005-12-15	Epitomics, Inc.	High-throughput method of DNA immunogen preparation and immunization
WO2005055932A2 (en) *	2003-12-02	2005-06-23	3M Innovative Properties Company	Therapeutic combinations and methods including irm compounds
US20050226878A1 (en) *	2003-12-02	2005-10-13	3M Innovative Properties Company	Therapeutic combinations and methods including IRM compounds
AU2004308964B2 (en)	2003-12-23	2010-09-16	Arbor Vita Corporation	Antibodies for oncogenic strains of HPV and methods of their use
JP4817599B2 (ja) *	2003-12-25	2011-11-16	独立行政法人科学技術振興機構	免疫活性増強剤とこれを用いた免疫活性の増強方法
JP2007517035A (ja) *	2003-12-29	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	アリールアルケニルおよびアリールアルキニル置換されたイミダゾキノリン
JP2007517055A (ja) *	2003-12-30	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	免疫応答の増強
JP2007517044A (ja) *	2003-12-30	2007-06-28	スリーエムイノベイティブプロパティズカンパニー	イミダゾキノリニル、イミダゾピリジニル、およびイミダゾナフチリジニルスルホンアミド
WO2005072290A2 (en) *	2004-01-23	2005-08-11	Joslin Diabetes Center	Methods of treating, reducing, or preventing autoimmune conditions
WO2005076972A2 (en)	2004-02-05	2005-08-25	The Ohio State University Research Foundation	Chimeric vegf peptides
US20050181035A1 (en) *	2004-02-17	2005-08-18	Dow Steven W.	Systemic immune activation method using non CpG nucleic acids
CA2555390C (en)	2004-02-19	2014-08-05	Coley Pharmaceutical Group, Inc.	Immunostimulatory viral rna oligonucleotides
US20050208482A1 (en) *	2004-03-16	2005-09-22	Cohen David I	Tat-based immunomodulatory compositions and methods for their discovery and use
CA2559458A1 (en)	2004-03-19	2005-10-06	Xiu-Min Li	Herbal therapy for the treatment of food allergy
TW200612932A (en) *	2004-03-24	2006-05-01	3M Innovative Properties Co	Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines
TWI235440B (en) *	2004-03-31	2005-07-01	Advanced Semiconductor Eng	Method for making leadless semiconductor package
JP2007532572A (ja) *	2004-04-09	2007-11-15	スリーエムイノベイティブプロパティズカンパニー	免疫反応調整剤を送達させるための方法、組成物および調製物
WO2006126981A2 (en) *	2004-04-28	2006-11-30	3M Innovative Properties Company	Compositions and methods for mucosal vaccination
EP1751612B1 (en)	2004-05-06	2009-02-25	The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services	Methods and compositions for the treatment of uveitis
US20080199493A1 (en)	2004-05-25	2008-08-21	Picker Louis J	Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
ES2560449T3 (es)	2004-05-28	2016-02-19	Oryxe	Una mezcla para administración transdérmica de compuestos de peso molecular bajo y alto
US20050267145A1 (en) *	2004-05-28	2005-12-01	Merrill Bryon A	Treatment for lung cancer
US8017779B2 (en) *	2004-06-15	2011-09-13	3M Innovative Properties Company	Nitrogen containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines
US20070259881A1 (en) *	2004-06-18	2007-11-08	Dellaria Joseph F Jr	Substituted Imidazo Ring Systems and Methods
US7915281B2 (en) *	2004-06-18	2011-03-29	3M Innovative Properties Company	Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and method
WO2006009826A1 (en) *	2004-06-18	2006-01-26	3M Innovative Properties Company	Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US7897609B2 (en) *	2004-06-18	2011-03-01	3M Innovative Properties Company	Aryl substituted imidazonaphthyridines
AU2005335104C1 (en)	2004-07-18	2010-10-28	Csl Limited	Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
EP1773884B1 (en)	2004-08-03	2012-03-07	Innate Pharma	Therapeutic and diagnostic methods and compositions targeting 4ig-b7-h3 and its counterpart nk cell receptor
GB0417494D0 (en)	2004-08-05	2004-09-08	Glaxosmithkline Biolog Sa	Vaccine
EP1786450A4 (en) *	2004-08-27	2009-11-11	3M Innovative Properties Co	HIV IMMUNOSTIMATORY COMPOSITIONS
US20090270443A1 (en) *	2004-09-02	2009-10-29	Doris Stoermer	1-amino imidazo-containing compounds and methods
RU2402347C2 (ru)	2004-09-22	2010-10-27	ГлаксоСмитКлайн Байолоджикалз с.а.	Иммуногенная композиция
ES2344739T3 (es)	2004-09-24	2010-09-06	Intercell Ag	Proteina capsidial vp1 modificada del parvovirus b19.
JP2008000001A (ja) *	2004-09-30	2008-01-10	Osaka Univ	免疫刺激オリゴヌクレオチドおよびその医薬用途
WO2006042254A2 (en) *	2004-10-08	2006-04-20	3M Innovative Properties Company	Adjuvant for dna vaccines
DK3312272T3 (da)	2004-10-08	2019-12-02	Us Gov Health & Human Services	Modulering af replikationstilpasning ved brug a mindre optrædende synonyme kodoner
MY159370A (en) *	2004-10-20	2016-12-30	Coley Pharm Group Inc	Semi-soft-class immunostimulatory oligonucleotides
US7332324B2 (en)	2004-12-03	2008-02-19	University Of Toledo	Attenuated vaccine useful for immunizations against Coccidioides spp. infections
WO2006063072A2 (en) *	2004-12-08	2006-06-15	3M Innovative Properties Company	Immunomodulatory compositions, combinations and methods
US9809824B2 (en)	2004-12-13	2017-11-07	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	CpG oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
US8461174B2 (en)	2004-12-30	2013-06-11	3M Innovative Properties Company	Treatment for cutaneous metastases
CA2592904C (en)	2004-12-30	2015-04-07	3M Innovative Properties Company	Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP5313502B2 (ja)	2004-12-30	2013-10-09	スリーエムイノベイティブプロパティズカンパニー	置換キラル縮合［１，２］イミダゾ［４，５−ｃ］環状化合物
EP1855715B1 (en)	2005-01-27	2013-03-13	Children's Hospital & Research Center at Oakland	Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
AU2006210392A1 (en)	2005-02-04	2006-08-10	Coley Pharmaceutical Group, Inc.	Aqueous gel formulations containing immune response modifiers
WO2006086634A2 (en)	2005-02-11	2006-08-17	Coley Pharmaceutical Group, Inc.	Oxime and hydroxylamine substituted imidazo[4,5-c] ring compounds and methods
CN101160401A (zh) *	2005-02-24	2008-04-09	科勒制药集团公司	免疫刺激寡核苷酸
GB0504436D0 (en)	2005-03-03	2005-04-06	Glaxosmithkline Biolog Sa	Vaccine
US8101345B1 (en)	2005-03-25	2012-01-24	Isis Pharmaceuticals, Inc.	Proinflammatory nucleic acids
CN103372206A (zh)	2005-03-31	2013-10-30	葛兰素史密丝克莱恩生物有限公司	针对衣原体感染的疫苗
WO2006107853A2 (en)	2005-04-01	2006-10-12	Coley Pharmaceutical Group, Inc.	Pyrazolopyridine-1,4-diamines and analogs thereof
EP1863814A1 (en)	2005-04-01	2007-12-12	Coley Pharmaceutical Group, Inc.	1-substituted pyrazolo (3,4-c) ring compounds as modulators of cytokine biosynthesis for the treatment of viral infections and neoplastic diseases
CN101193646A (zh) *	2005-04-08	2008-06-04	科勒制药集团公司	治疗传染病加剧性哮喘的方法
JP2008538354A (ja) *	2005-04-08	2008-10-23	キメリクス，インコーポレイテッド	ウイルス感染症およびその他の内科疾患を治療するための化合物、組成物および方法
US8642577B2 (en)	2005-04-08	2014-02-04	Chimerix, Inc.	Compounds, compositions and methods for the treatment of poxvirus infections
AU2006241166A1 (en)	2005-04-25	2006-11-02	3M Innovative Properties Company	Immunostimulatory compositions
WO2006116458A2 (en) *	2005-04-26	2006-11-02	Coley Pharmaceutical Gmbh	Modified oligoribonucleotide analogs with enhances immunostimulatory activity
ES2381492T3 (es)	2005-04-29	2012-05-28	Glaxosmithkline Biologicals Sa	Procedimiento de prevención o tratamiento de infección por M. tuberculosis
NZ564954A (en)	2005-06-14	2011-02-25	Protox Therapeutics Inc	Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
WO2006138675A2 (en)	2005-06-15	2006-12-28	The Ohio State University Research Foundation	Her-2 peptides
GB0513421D0 (en)	2005-06-30	2005-08-03	Glaxosmithkline Biolog Sa	Vaccines
US8148341B2 (en)	2005-07-01	2012-04-03	Index Pharmaceuticals Ab	Method for modulating responsiveness to steroids
PL2380584T3 (pl)	2005-07-01	2014-03-31	Index Pharmaceuticals Ab	Sposób do immunostymulacji
KR20080030656A (ko) *	2005-07-07	2008-04-04	콜레이 파마시티컬 그룹, 인코포레이티드	암 치료를 위한 항-ＣＴＬＡ-4 항체 및 ＣｐＧ-모티프-함유합성 올리고데옥시뉴클레오티드의 조합 요법
US20080206276A1 (en) *	2005-07-08	2008-08-28	Michael Otto	Targeting Poly-Gamma-Glutamic Acid to Treat Staphylococcus Epidermidis and Related Infections
JP2009500454A (ja)	2005-07-11	2009-01-08	グローブイミューン，インコーポレイテッド	標的化治療の変異型を回避する免疫応答を惹起するための組成物および方法
WO2007117264A2 (en)	2005-08-03	2007-10-18	Fraunhofer Usa, Inc.	Compositions and methods for production of immunoglobulins
US20100130425A1 (en)	2005-09-09	2010-05-27	Oregon Health & Science University	Use of toll-like receptor ligands in treating excitotoxic injury, ischemia and/or hypoxia
CN101321868A (zh) *	2005-09-16	2008-12-10	科利制药公司	通过核苷酸修饰调节短干扰核糖核酸(siRNA)的免疫刺激特性
CN101310019A (zh) *	2005-09-16	2008-11-19	科利制药公司	具有磷酸二酯主链的免疫刺激性单链核糖核酸
US20070081972A1 (en) *	2005-09-30	2007-04-12	The University Of Iowa Research Foundation	Polymer-based delivery system for immunotherapy of cancer
EP1940472A1 (en)	2005-10-28	2008-07-09	Index Pharmaceuticals AB	Composition and method for the prevention, treatment and/or alleviation of an inflammatory disease
ES2536103T3 (es)	2005-11-25	2015-05-20	Zoetis Belgium S.A.	Oligorribonucleótidos inmunoestimuladores
DK2347775T3 (da)	2005-12-13	2020-07-13	Harvard College	Skabeloner til celletransplantation
CA2636139A1 (en)	2005-12-14	2007-06-21	Cytos Biotechnology Ag	Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
GB0607088D0 (en)	2006-04-07	2006-05-17	Glaxosmithkline Biolog Sa	Vaccine
DK2384765T3 (da)	2005-12-22	2017-01-09	Glaxosmithkline Biologicals Sa	Vaccine mod Streptococcus pneumoniae.
EP1981905B1 (en)	2006-01-16	2016-08-31	THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES	Chlamydia vaccine
UA92782C2 (ru)	2006-01-17	2010-12-10	Арне Форсгрен	Новый поверхностный белок haemophilus influenzae (белок е; ре)
JP2009526526A (ja)	2006-02-13	2009-07-23	フラウンホーファーユーエスエー，インコーポレイテッド	インフルエンザ抗原、ワクチン組成物、および関連する方法
JP5473336B2 (ja)	2006-02-15	2014-04-16	アディウタイド・ファーマスーティカルズ・ゲーエムベーハー	オリゴヌクレオチドの処方に関する組成物および方法
US8951528B2 (en) *	2006-02-22	2015-02-10	3M Innovative Properties Company	Immune response modifier conjugates
EP2397855A3 (en)	2006-03-14	2012-03-14	Oregon Health and Science University	Methods for detecting a mycobacterium tuberculosis infection
WO2007113222A2 (en)	2006-03-30	2007-10-11	Glaxosmithkline Biologicals S.A.	Immunogenic composition
EP2017281A4 (en)	2006-04-14	2012-03-14	Kyowa Hakko Kirin Co Ltd	AGONISTS AT TOLL-LIKE RECEPTOR 9
CN101460620B (zh)	2006-05-31	2012-02-15	东丽株式会社	免疫刺激寡核苷酸及其药物用途
KR20090017655A (ko)	2006-06-02	2009-02-18	글락소스미스클라인 바이오로지칼즈 에스.에이.	환자가 면역치료제에 대한 반응자일지의 여부를 확인하는 방법
KR100906970B1 (ko)	2006-06-03	2009-07-10	주식회사 바이오씨에스	피부 면역질환에 대한 ＣｐＧ 올리고데옥시뉴클레오티드의치료학적 용도
US20080026986A1 (en) *	2006-06-05	2008-01-31	Rong-Fu Wang	Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
EP2530086B1 (en)	2006-06-12	2019-03-20	Kuros Biosciences AG	Processes for packaging oligonucleotides into virus-like particles of RNA bacteriophages
US20090123499A1 (en)	2006-06-12	2009-05-14	Nathalie Devos	Vaccine
EP2292648A3 (en)	2006-07-07	2011-06-08	Intercell AG	Small Streptococcus pyogenes antigens and their use
US8153116B2 (en)	2006-07-11	2012-04-10	University Of Connecticut	Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
US8128921B2 (en) *	2006-07-11	2012-03-06	University Of Connecticut	Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
WO2008008432A2 (en) *	2006-07-12	2008-01-17	Coley Pharmaceutical Group, Inc.	Substituted chiral fused( 1,2) imidazo (4,5-c) ring compounds and methods
DE102006035618A1 (de) *	2006-07-31	2008-02-07	Curevac Gmbh	Nukleinsäure der Formel (I): GlXmGn, insbesondere als immunstimulierendes Adjuvanz
EP2046954A2 (en)	2006-07-31	2009-04-15	Curevac GmbH	NUCLEIC ACID OF FORMULA (I): GIXmGn, OR (II): CIXmCn, IN PARTICULAR AS AN IMMUNE-STIMULATING AGENT/ADJUVANT
CN103585624A (zh)	2006-09-07	2014-02-19	葛兰素史密丝克莱恩生物有限公司	疫苗
AU2007295927A1 (en)	2006-09-15	2008-03-20	Intercell Ag	Borrelia antigens
WO2008153541A1 (en)	2006-09-26	2008-12-18	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
US20090181078A1 (en)	2006-09-26	2009-07-16	Infectious Disease Research Institute	Vaccine composition containing synthetic adjuvant
MX2009003398A (es) *	2006-09-27	2009-08-12	Coley Pharm Gmbh	Analogos de oligonucleotidos cpg que contienen analogos t hidrofobos con actividad inmunoestimuladora mejorada.
EP2104738A2 (en) *	2006-10-26	2009-09-30	Coley Pharmaceuticals GmbH	Oligoribonucleotides and uses thereof
CA3125026C (en)	2006-11-01	2023-04-04	Ventana Medical Systems, Inc.	Haptens, hapten conjugates, compositions thereof and method for their preparation and use
US20090142362A1 (en) *	2006-11-06	2009-06-04	Avant Immunotherapeutics, Inc.	Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (CETP)
PL2094849T3 (pl) *	2006-11-09	2014-06-30	Dynavax Tech Corp	Długotrwała zmiana przebiegu choroby z zastosowaniem oligonukleotydów immunostymulujących
EP1923069A1 (en)	2006-11-20	2008-05-21	Intercell AG	Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US20080149123A1 (en) *	2006-12-22	2008-06-26	Mckay William D	Particulate material dispensing hairbrush with combination bristles
EP2269624A3 (en)	2007-01-12	2012-08-08	Intercell AG	Protective proteins of S. agalactiae, combinations thereof and methods of using the same
CA2678404C (en)	2007-02-28	2019-03-19	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Brachyury polypeptides and methods for use
CL2008000611A1 (es)	2007-03-02	2008-09-05	Glaxosmithkline Biolog Sa	Procedimiento para fomentar respuesta inmunitaria frente a un patogeno que comprende administrar i) uno o mas polipeptidos inmunogenicos derivados del patogeno, ii) uno o mas vectores adenoviricos que comprenden uno o mas polinucleotidos que codifica
MX2009009530A (es) *	2007-03-07	2010-05-19	Nventa Biopharmaceuticals Corp	Composiciones de acidos nucleicos cerrados bicatenarios.
WO2008115610A1 (en)	2007-03-19	2008-09-25	Globeimmune, Inc.	Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
PL2136836T3 (pl)	2007-04-04	2017-07-31	Infectious Disease Research Institute	Kompozycje immunogenne zawierające polipeptydy prątka gruźlicy i produkty ich fuzji
US9452209B2 (en)	2007-04-20	2016-09-27	Glaxosmithkline Biologicals Sa	Influenza vaccine
BRPI0810865A2 (pt)	2007-04-28	2017-05-09	Fraunhofer Usa Inc	antígenos de tripanossoma, composições vacinais, e métodos relacionados
EP2489673A3 (en)	2007-05-02	2012-09-12	Intercell AG	Klebsiella antigens
EP2142211A1 (en)	2007-05-02	2010-01-13	GlaxoSmithKline Biologicals S.A.	Vaccine
EP2573176B1 (en) *	2007-05-04	2016-04-06	InDex Pharmaceuticals AB	Tumour growth inhibitory compounds and methods of their use
US20100285041A1 (en) *	2007-05-17	2010-11-11	Eugen Uhlmann	Class A Oligonucleotides with Immunostimulatory Potency
HRP20150769T1 (hr) *	2007-05-18	2015-08-28	Adiutide Pharmaceuticals Gmbh	Oligonukleotidni analozi s modificiranim fosfatima, s imunostimulirajuä†om aktivnošä†u
DK2167963T3 (da)	2007-05-23	2019-06-24	Ventana Med Syst Inc	Polymerbærere til immunhistokemi og in situ-hybridisering
MX2009012381A (es)	2007-05-24	2009-12-01	Glaxosmithkline Biolog Sa	Composicion antigenica liofilizada.
ES2602610T3 (es)	2007-05-31	2017-02-21	Medigene Ag	Proteína estructural mutada de un parvovirus
EP2012122A1 (en)	2007-07-06	2009-01-07	Medigene AG	Mutated parvovirus structural proteins as vaccines
CN101883782A (zh)	2007-06-18	2010-11-10	英特塞尔股份公司	衣原体抗原
EP2687228B1 (en)	2007-06-26	2017-07-19	GlaxoSmithKline Biologicals S.A.	Vaccine comprising streptococcus pneumoniae capsular polysaccharide conjugates
EP2170384B1 (en)	2007-07-02	2016-04-13	Etubics Corporation	Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
WO2009009759A2 (en)	2007-07-11	2009-01-15	Fraunhofer Usa, Inc.	Yersinia pestis antigens, vaccine compositions, and related methods
MX2010001284A (es)	2007-08-02	2010-08-31	Biondvax Pharmaceuticals Ltd	Vacunas contra la influenza con multiepitope multimerico.
CN102027003A (zh)	2007-08-03	2011-04-20	哈佛大学校长及研究员协会	衣原体抗原
US7879812B2 (en)	2007-08-06	2011-02-01	University Of Iowa Research Foundation	Immunomodulatory oligonucleotides and methods of use therefor
JP5508266B2 (ja)	2007-08-13	2014-05-28	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
CA2697049A1 (en) *	2007-08-21	2009-02-26	Dynavax Technologies Corporation	Composition and methods of making and using influenza proteins
JP2010536907A (ja) *	2007-08-31	2010-12-02	ニューリミューンセラピューティクスエイジー	患者にアミロイドーシスおよびタンパク質凝集性障害における特異的免疫応答をもたらす方法
WO2009030254A1 (en)	2007-09-04	2009-03-12	Curevac Gmbh	Complexes of rna and cationic peptides for transfection and for immunostimulation
JP5406839B2 (ja)	2007-09-17	2014-02-05	オンコメチロームサイエンシズソシエテアノニム	Ｍａｇｅ−ａ発現の改良された検出
KR20100068422A (ko)	2007-10-09	2010-06-23	콜리 파마슈티칼 게엠베하	변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
SG187482A1 (en)	2007-11-07	2013-02-28	Celldex Therapeutics Inc	Antibodies that bind human dendritic and epithelial cell 205 (dec-205)
EP2902495B1 (en)	2007-11-09	2019-12-25	The Salk Institute for Biological Studies	Use of tam receptor activators as immunosuppressors
CA2744739A1 (en)	2007-12-03	2009-06-11	President And Fellows Of Harvard College	Chlamydia antigens
WO2009076158A1 (en)	2007-12-07	2009-06-18	Novartis Ag	Compositions for inducing immune responses
SI2222710T1 (sl)	2007-12-24	2016-11-30	Id Biomedical Corporation Of Quebec	Rekombinatni RSV antigeni
CN102670628B (zh) *	2008-01-25	2015-11-25	奇默里克斯公司	治疗病毒感染的方法
KR101483715B1 (ko)	2008-01-31	2015-01-19	큐어백 게엠바하	면역증강제／애주번트인 화학식（ＮｕＧｌＸｍＧｎＮｖ）ａ를 포함하는 핵산 및 이의 유도체
EP2254602B1 (en)	2008-02-13	2018-11-21	President and Fellows of Harvard College	Continuous cell programming devices
WO2009105641A2 (en)	2008-02-20	2009-08-27	New York University	Preventing and treating amyloid-beta deposition by stimulation of innate immunity
EP2265640B1 (en)	2008-03-10	2015-11-04	Children's Hospital & Research Center at Oakland	Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
JP2011514167A (ja)	2008-03-17	2011-05-06	インターセルアーゲー	肺炎連鎖球菌（Ｓ．ｐｎｅｕｍｏｎｉａｅ）に対して保護的なペプチドならびにそれに関連する組成物、方法、および使用
JP2011518186A (ja)	2008-04-18	2011-06-23	ザジェネラルホスピタルコーポレイション	自己集合性ワクチンを使用する免疫療法
US8815817B2 (en) *	2008-05-15	2014-08-26	Dynavax Technologies Corporation	Long term disease modification using immunostimulatory oligonucleotides
US8222225B2 (en)	2008-05-21	2012-07-17	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Method of treating pneumoconiosis with oligodeoxynucleotides
US9415006B2 (en)	2008-05-23	2016-08-16	The Regents Of The University Of Michigan	Immunogenic compositions comprising nanoemulsion and hepatitis B virus immunogen and methods of using the same
US8703490B2 (en)	2008-06-05	2014-04-22	Ventana Medical Systems, Inc.	Compositions comprising nanomaterials and method for using such compositions for histochemical processes
TWI351288B (en) *	2008-07-04	2011-11-01	Univ Nat Pingtung Sci & Tech	Cpg dna adjuvant in avian vaccines
RU2011107757A (ru)	2008-08-01	2012-09-10	Гамма Ваксинс Пти Лимитед (Au)	Вакцины против гриппа
JP2012503206A (ja)	2008-09-22	2012-02-02	オレゴンヘルスアンドサイエンスユニバーシティ	Ｍｙｃｏｂａｃｔｅｒｉｕｍｔｕｂｅｒｃｕｌｏｓｉｓ感染を検出するための方法
CN102223876A (zh)	2008-09-26	2011-10-19	纳米生物公司	纳米乳剂治疗性组合物及其使用方法
WO2010037046A1 (en)	2008-09-28	2010-04-01	Fraunhofer Usa, Inc.	Humanized neuraminidase antibody and methods of use thereof
WO2010037408A1 (en)	2008-09-30	2010-04-08	Curevac Gmbh	Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
HUE028497T2 (en) *	2008-10-16	2016-12-28	The Univ Of Saskatchewan	Combination adjuvant composition
WO2010048572A1 (en)	2008-10-23	2010-04-29	Cornell University	A novel anti-viral method
WO2010048731A1 (en) *	2008-10-31	2010-05-06	Christopher John Ong	Aminoacyl trna-synthetase inhibitors as broad-spectrum immunosuppressive agents
EP2376089B1 (en)	2008-11-17	2018-03-14	The Regents of the University of Michigan	Cancer vaccine compositions and methods of using the same
EP2398466B1 (en)	2008-11-24	2021-02-17	Massachusetts Institute of Technology	Methods and compositions for localized nanoparticle delivery to a tumor
SG171914A1 (en)	2008-12-02	2011-07-28	Chiralgen Ltd	Method for the synthesis of phosphorus atom modified nucleic acids
CA2745205A1 (en)	2008-12-03	2010-06-10	Protea Vaccine Technologies Ltd.	Glutamyl trna synthetase (gts) fragments
JP2012510284A (ja)	2008-12-03	2012-05-10	プロイェクト、デ、ビオメディシナ、シーマ、ソシエダッド、リミターダ	ワクチンの開発のためのフェノール可溶性モジュリンの使用
US8552165B2 (en)	2008-12-09	2013-10-08	Heather Davis	Immunostimulatory oligonucleotides
AU2009325950B2 (en) *	2008-12-09	2013-03-07	Pfizer Vaccines Llc	IgE CH3 peptide vaccine
CA2745096C (en)	2008-12-09	2013-11-05	Coley Pharmaceutical Group, Inc.	Immunostimulatory oligonucleotides
CN102307477B (zh)	2009-01-05	2015-07-29	埃皮托吉尼西斯股份有限公司	佐剂组合物及使用方法
SG173065A1 (en)	2009-01-20	2011-08-29	Transgene Sa	Soluble icam-1 as biomarker for prediction of therapeutic response
US20100234283A1 (en)	2009-02-04	2010-09-16	The Ohio State University Research Foundation	Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
EP2424882A2 (en)	2009-02-05	2012-03-07	Intercell AG	Peptides protective against e. faecalis, methods and uses relating thereto
WO2010092176A2 (en)	2009-02-13	2010-08-19	Intercell Ag	Nontypable haemophilus influenzae antigens
US8664183B2 (en)	2009-02-27	2014-03-04	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	SPANX-B polypeptides and their use
SG174877A1 (en)	2009-03-17	2011-11-28	Mdxhealth Sa	Improved detection of gene expression
US8530431B2 (en)	2009-03-23	2013-09-10	Pin Pharma, Inc.	Treatment of cancers with immunostimulatory HIV TAT derivative polypeptides
CA2756133A1 (en)	2009-03-24	2010-09-30	Transgene S.A.	Biomarker for monitoring cancer patients
RU2015117604A (ru)	2009-04-03	2015-10-27	Эйдженус Инк.	Способы получения и применения мультишаперон-антигенных комплексов
MX2011010920A (es)	2009-04-17	2011-11-04	Transgene Sa	Biomarcador para monitorear pacientes.
KR20120022984A (ko) *	2009-04-21	2012-03-12	셀렉타 바이오사이언시즈, 인크.	Ｔｈ１ 편향 반응을 제공하는 면역나노치료법
KR101450958B1 (ko)	2009-04-30	2014-10-15	콜레이 파마시티컬 그룹, 인코포레이티드	폐렴구균 백신 및 그의 용도
JP6282395B2 (ja)	2009-05-27	2018-02-21	セレクタバイオサイエンシーズインコーポレーテッドＳｅｌｅｃｔａＢｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ．	異なる放出速度の構成要素を有するナノキャリア
CN102459324B (zh)	2009-05-27	2014-07-09	葛兰素史密丝克莱恩生物有限公司	Casb7439构建体
EP3124491B1 (en)	2009-06-05	2019-10-30	Infectious Disease Research Institute	Synthetic glucopyranosyl lipid adjuvants and vaccine compositions as well as pharmaceutical compositions containing them
ES2566646T3 (es)	2009-06-16	2016-04-14	The Regents Of The University Of Michigan	Vacunas en nanoemulsión
MX2012000036A (es)	2009-06-24	2012-02-28	Glaxosmithkline Biolog Sa	Vacuna.
JP6062245B2 (ja)	2009-06-24	2017-01-18	グラクソスミスクラインバイオロジカルズソシエテアノニム	組換えｒｓｖ抗原
IN2012DN00720A (da)	2009-07-06	2015-06-19	Ontorii Inc
ES2558729T3 (es)	2009-07-10	2016-02-08	Transgene Sa	Biomarcador para la selección de pacientes y procedimientos relacionados
SG178026A1 (en)	2009-07-15	2012-03-29	Novartis Ag	Rsv f protein compositions and methods for making same
WO2011011519A1 (en)	2009-07-21	2011-01-27	Chimerix, Inc.	Compounds, compositions and methods for treating ocular conditions
RU2518291C2 (ru) *	2009-07-30	2014-06-10	Пфайзер Вэксинс ЭлЭлСи	Антигенные tau-пептиды и их применения
US20110033515A1 (en) *	2009-08-04	2011-02-10	Rst Implanted Cell Technology	Tissue contacting material
GB0913681D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
GB0913680D0 (en)	2009-08-05	2009-09-16	Glaxosmithkline Biolog Sa	Immunogenic composition
WO2011025286A2 (ko)	2009-08-26	2011-03-03	주식회사 알엔에이	리포테이코익산 유래 당지질 및 이를 포함하는 조성물
WO2011026111A1 (en)	2009-08-31	2011-03-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Oral delivery of a vaccine to the large intestine to induce mucosal immunity
EP3358008A1 (en)	2009-09-03	2018-08-08	Pfizer Vaccines LLC	Pcsk9 vaccine
US20110053829A1 (en)	2009-09-03	2011-03-03	Curevac Gmbh	Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2477642A4 (en) *	2009-09-17	2013-03-13	Mutual Pharmaceutical Co	METHOD FOR THE TREATMENT OF ASTHMA WITH ANTIVIRUS AGENTS
GB0917457D0 (en)	2009-10-06	2009-11-18	Glaxosmithkline Biolog Sa	Method
CA2776144C (en)	2009-09-29	2020-10-27	Fraunhofer Usa, Inc.	Influenza hemagglutinin antibodies, compositions, and related methods
CA2776922A1 (en)	2009-10-07	2011-04-14	Uvic Industry Partnerships Inc.	Vaccines comprising heat-sensitive transgenes
EP2319871A1 (en)	2009-11-05	2011-05-11	Sanofi-aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
CN102686611A (zh)	2009-10-09	2012-09-19	赛诺菲	与“渐进性糖化终产物受体”结合的多肽以及包括所述多肽的组合物和方法
EP2308896A1 (en)	2009-10-09	2011-04-13	Sanofi-aventis	Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same
WO2011047340A1 (en)	2009-10-16	2011-04-21	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
GB0919117D0 (en)	2009-10-30	2009-12-16	Glaxosmithkline Biolog Sa	Process
EP2501397B1 (en)	2009-11-20	2017-10-04	Oregon Health and Science University	Methods for producing an immune response to tuberculosis
WO2011067758A2 (en)	2009-12-02	2011-06-09	Protea Vaccine Technologies Ltd.	Immunogenic fragments and multimers from streptococcus pneumoniae proteins
CA2785585A1 (en)	2009-12-22	2011-06-30	Celldex Therapeutics, Inc.	Vaccine compositions
FR2954703B1 (fr)	2009-12-28	2013-12-13	Chu Nantes	Agonistes des recepteurs tlr 4 et 9 pour prevenir les complications septiques de l'immunodepression post-traumatique chez les patients hospitalises pour traumatismes severes
HUE032860T2 (en)	2010-02-12	2017-11-28	Chimerix Inc	A method for treating a virus infection
WO2011101332A1 (en)	2010-02-16	2011-08-25	Proyecto De Biomedicina Cima, S.L.	Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
WO2011109422A2 (en)	2010-03-02	2011-09-09	The United States Of America, Represented By The Secretary, Department Of Health And Human Services	Compositions and methods for the treatment of cancer
CA2792258A1 (en)	2010-03-05	2011-09-09	President And Fellows Of Harvard College	Induced dendritic cell compositions and uses thereof
GB201003924D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Immunogenic composition
GB201003920D0 (en)	2010-03-09	2010-04-21	Glaxosmithkline Biolog Sa	Method of treatment
WO2011110634A1 (en)	2010-03-10	2011-09-15	Glaxosmithkline Biologicals S.A.	Vaccine composition
WO2011112599A2 (en)	2010-03-12	2011-09-15	The United States Of America, As Represented By The Secretary. Department Of Health & Human Services	Immunogenic pote peptides and methods of use
WO2011115684A2 (en)	2010-03-19	2011-09-22	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
US9149432B2 (en)	2010-03-19	2015-10-06	Massachusetts Institute Of Technology	Lipid vesicle compositions and methods of use
US20110229556A1 (en) *	2010-03-19	2011-09-22	Massachusetts Institute Of Technology	Lipid-coated polymer particles for immune stimulation
GB201005005D0 (en)	2010-03-25	2010-05-12	Angeletti P Ist Richerche Bio	New vaccine
CN110845585A (zh)	2010-03-30	2020-02-28	奥克兰儿童医院及研究中心	改性的h因子结合蛋白（fhbp）及其使用方法
ES2608475T3 (es)	2010-04-13	2017-04-11	Celldex Therapeutics, Inc.	Anticuerpos que se unen a cd27 humana y usos de los mismos
US9278135B2 (en)	2010-04-26	2016-03-08	Chimerix Inc.	Methods of treating retroviral infections and related dosage regimes
PL3333265T3 (pl)	2010-05-14	2020-08-10	Oregon Health & Science University	Rekombinowane wektory HCMV i RHCMV kodujące heterologiczny antygen wyizolowany z wirusa zapalenia wątroby typu B oraz ich zastosowania
NO2575876T3 (da)	2010-05-26	2018-05-05
CA2800158C (en) *	2010-05-28	2020-07-21	Coley Pharmaceutical Group, Inc.	Vaccines comprising cholesterol and cpg as sole adjuvant-carrier molecules
EP2575868A1 (en)	2010-06-07	2013-04-10	Pfizer Vaccines LLC	Ige ch3 peptide vaccine
US8658603B2 (en)	2010-06-16	2014-02-25	The Regents Of The University Of Michigan	Compositions and methods for inducing an immune response
BR112013002298A2 (pt)	2010-07-30	2016-05-24	Curevac Gmbh	complexação de ácidos nucleicos com componentes catiônicos reticulados com dissulfeto para transfecção e estimulação imunológica.
CN103957931B (zh)	2010-09-03	2017-10-24	瓦尔内瓦奥地利有限责任公司	艰难梭状芽胞杆菌毒素a和毒素b蛋白的分离多肽及其用途
AR082925A1 (es)	2010-09-08	2013-01-16	Medigene Ag	Proteinas estructurales mutadas por parvovirus con epitopo de celulas b de proteccion cruzada, producto y metodos relacionados
GB201015132D0 (en)	2010-09-10	2010-10-27	Univ Bristol	Vaccine composition
WO2012036993A1 (en)	2010-09-14	2012-03-22	University Of Pittsburgh-Of The Commonwealth System Of Higher Education	Computationally optimized broadly reactive antigens for influenza
WO2012039448A1 (ja)	2010-09-24	2012-03-29	株式会社キラルジェン	不斉補助基
BR112013004582A2 (pt)	2010-09-27	2016-09-06	Crucell Holland Bv	método para induzir uma resposta imune em um sujeito contra um antígeno de um parasita que causa a malária
PL2624873T3 (pl)	2010-10-06	2020-12-14	President And Fellows Of Harvard College	Nadające się do wstrzykiwania hydrożele tworzące pory do terapii komórkowych opartych na materiałach
WO2012057904A1 (en)	2010-10-27	2012-05-03	Infectious Disease Research Institute	Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
EP2640190A4 (en)	2010-11-05	2016-05-11	Selecta Biosciences Inc	MODIFIED NICOTINIC COMPOUNDS AND ASSOCIATED METHODS
US20120114688A1 (en)	2010-11-08	2012-05-10	Infectious Disease Research Institute	Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
SG190731A1 (en)	2010-12-14	2013-07-31	Glaxosmithkline Biolog Sa	Mycobacterium antigenic composition
EP2667891B1 (en)	2011-01-27	2021-10-06	Gamma Vaccines Pty Limited	Combination vaccines
CA2828068C (en)	2011-02-22	2019-03-19	Biondvax Pharmaceuticals Ltd.	Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP2680883B1 (en)	2011-03-02	2018-09-05	Pfizer Inc	Pcsk9 vaccine
EP2505640A1 (en)	2011-03-29	2012-10-03	Neo Virnatech, S.L.	Vaccine compositions for birnavirus-borne diseases
GB201106357D0 (en)	2011-04-14	2011-06-01	Pessi Antonello	Composition and uses thereof
AU2012243039B2 (en)	2011-04-08	2017-07-13	Immune Design Corp.	Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
TW201302779A (zh)	2011-04-13	2013-01-16	Glaxosmithkline Biolog Sa	融合蛋白質及組合疫苗
US20120288515A1 (en)	2011-04-27	2012-11-15	Immune Design Corp.	Synthetic long peptide (slp)-based vaccines
US9675561B2 (en)	2011-04-28	2017-06-13	President And Fellows Of Harvard College	Injectable cryogel vaccine devices and methods of use thereof
BR112013029169B1 (pt)	2011-05-13	2021-09-28	Novartis Ag	Polipeptídeo f pré-fusão do vírus sincicial respiratório (rsv), composição imunogênica e uso da mesma
FR2975600B1 (fr)	2011-05-24	2013-07-05	Assist Publ Hopitaux De Paris	Agents pour le traitement de tumeurs
RU2606114C2 (ru)	2011-06-01	2017-01-10	Джейнус Байотерапьютикс, Инк.	Новые модуляторы иммунной системы
CA2837207A1 (en)	2011-06-01	2012-12-06	Janus Biotherapeutics, Inc.	Novel immune system modulators
JP6460789B2 (ja)	2011-06-03	2019-01-30	スリーエムイノベイティブプロパティズカンパニー	ポリエチレングリコールセグメントを有するヘテロ２官能性リンカー及び該リンカーから調製された免疫反応調節複合体
JP6415979B2 (ja)	2011-06-03	2018-10-31	スリーエムイノベイティブプロパティズカンパニー	ヒドラジノ１ｈ−イミダゾキノリン−４−アミン及びこれから調製された複合体
EP2717909B1 (en)	2011-06-04	2017-12-06	Rochester General Hospital Research Institute	Compositions and methods related to p6 of haemophilus influenzae
CA2839932C (en)	2011-06-07	2022-07-05	Ibio, Inc.	In vivo de-glycosylation of recombinant proteins by co-expression with pngase f
US8697085B2 (en)	2011-06-17	2014-04-15	University Of Tennessee Research Foundation	Group A Streptococcus multivalent vaccine
RU2612900C2 (ru)	2011-06-20	2017-03-13	Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн	Антигены вируса гриппа h1n1 с широким спектром активности, оптимизированные с применением вычислительных средств
CN103608030A (zh)	2011-06-21	2014-02-26	昂科发克特公司	用于治疗和诊断癌症的组合物和方法
WO2013007703A1 (en) *	2011-07-08	2013-01-17	Universität Zürich	CLASS A CpG OLIGONUCLEOTIDES FOR PREVENTION OF VIRAL INFECTION IN CATS
MX347361B (es)	2011-07-19	2017-04-12	Wave Life Sciences Ltd	Metodos para la sintesis de acidos nucleicos funcionalizados.
US20130023736A1 (en)	2011-07-21	2013-01-24	Stanley Dale Harpstead	Systems for drug delivery and monitoring
US20130039954A1 (en)	2011-07-29	2013-02-14	Selecta Biosciences, Inc.	Control of antibody responses to synthetic nanocarriers
GB201114919D0 (en)	2011-08-30	2011-10-12	Glaxosmithkline Biolog Sa	Method
WO2013039792A1 (en)	2011-09-12	2013-03-21	The United States Of America As Represented By The Secretary, Department Of Health And Human Services	Immunogens based on an hiv-1 gp120 v1v2 epitope
EP3617227A3 (en)	2011-09-16	2020-06-03	UCB Biopharma SRL	Neutralising antibodies to the major exotoxin tcda of clostridium difficile
ES2548391T3 (es)	2011-09-21	2015-10-16	Ruprecht-Karls-Universität Heidelberg	Péptidos de cambio de marco (FSP) específicos de MSI para prevención y tratamiento del cáncer
WO2013049535A2 (en)	2011-09-30	2013-04-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Influenza vaccine
US9873694B2 (en)	2011-10-04	2018-01-23	Janus Biotherapeutics, Inc.	Imidazole quinoline-based immune system modulators
EP2768847A4 (en)	2011-10-20	2015-11-11	Us Gov Health & Human Serv	DENGUE VIRUS E-GLYCOPROTEIN POLYPEPTIDES WITH MUTATIONS FOR ELIMINATING IMMUNOMINANT CROSS-REACTIVE EPITOPES
WO2013074501A1 (en)	2011-11-14	2013-05-23	Crucell Holland B.V.	Heterologous prime-boost immunization using measles virus-based vaccines
EP2596806A1 (en)	2011-11-25	2013-05-29	Index Pharmaceuticals AB	Method for prevention of colectomy
SG10201605350UA (en)	2012-01-16	2016-08-30	Mckenna Elizabeth	Compositions and Methods for the Treatment of Hepatic Diseases and Disorders
US12268718B2 (en)	2012-01-16	2025-04-08	Labyrinth Holdings Llc	Control of cellular redox levels
WO2013113326A1 (en)	2012-01-31	2013-08-08	Curevac Gmbh	Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
RU2653756C2 (ru)	2012-02-07	2018-05-14	Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн	Оптимизированные с помощью компьютера антигены с широким спектром реактивности для вирусов гриппа h3n2
EP3563834A1 (en)	2012-02-07	2019-11-06	Infectious Disease Research Institute	Improved adjuvant formulations comprising tlr4 agonists and methods of using the same
EP3305806B1 (en)	2012-02-13	2020-08-26	University of Pittsburgh - Of the Commonwealth System of Higher Education	Computationally optimized broadly reactive antigens for human and avian h5n1 influenza
CA2866185C (en)	2012-03-23	2021-04-06	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Pathogenic phlebovirus isolates and compositions and methods of use
EP3492095A1 (en)	2012-04-01	2019-06-05	Technion Research & Development Foundation Limited	Extracellular matrix metalloproteinase inducer (emmprin) peptides and binding antibodies
PL2838515T3 (pl)	2012-04-16	2020-06-29	President And Fellows Of Harvard College	Kompozycje mezoporowatego krzemu do modulowania odpowiedzi odpornościowych
EP2841098A4 (en)	2012-04-23	2016-03-02	Allertein Therapeutics Llc	NANOPARTICLES FOR THE TREATMENT OF ALLERGIES
NZ701324A (en)	2012-05-04	2016-09-30	Pfizer	Prostate-associated antigens and vaccine-based immunotherapy regimens
EA034351B1 (ru)	2012-05-16	2020-01-30	Иммьюн Дизайн Корп.	Трехкомпонентная вакцина против впг-2 и способы ее применения
US9409956B2 (en)	2012-05-23	2016-08-09	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Salmonella typhi Ty21a expressing Yersinia pestis F1-V fusion protein and uses thereof
EP2666785A1 (en)	2012-05-23	2013-11-27	Affiris AG	Complement component C5a-based vaccine
CN104428008B (zh)	2012-05-24	2020-10-09	美国政府(由卫生和人类服务部的部长所代表)	多价脑膜炎球菌缀合物及制备缀合物的方法
US9687542B2 (en)	2012-06-19	2017-06-27	The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Rift valley fever virus replicon particles and use thereof
EP2872485B1 (en)	2012-07-13	2020-12-16	Wave Life Sciences Ltd.	Asymmetric auxiliary group
AU2013287630B2 (en)	2012-07-13	2017-05-25	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant
EP2872147B1 (en)	2012-07-13	2022-12-21	Wave Life Sciences Ltd.	Method for making chiral oligonucleotides
RU2659149C2 (ru)	2012-08-03	2018-06-28	Инфекшес Дизиз Рисерч Инститьют	Композиции и способы для лечения активной инфекции mycobacterium tuberculosis
CA2879939A1 (en)	2012-08-06	2014-02-13	Glaxosmithkline Biologicals S.A.	Novel method
US20140037680A1 (en)	2012-08-06	2014-02-06	Glaxosmithkline Biologicals, S.A.	Novel method
WO2014031178A1 (en)	2012-08-24	2014-02-27	Etubics Corporation	Replication defective adenovirus vector in vaccination
EP2703483A1 (en)	2012-08-29	2014-03-05	Affiris AG	PCSK9 peptide vaccine
WO2014037124A1 (en)	2012-09-04	2014-03-13	Bavarian Nordic A/S	Methods and compositions for enhancing vaccine immune responses
US10232035B2 (en)	2012-09-14	2019-03-19	The Regents Of The University Of Colorado, A Body Corporate	Conditionally replication deficient herpes virus and use thereof in vaccines
EP2895191B1 (en)	2012-09-14	2019-06-05	The U.S.A. as represented by the Secretary, Department of Health and Human Services	Brachyury protein, adenoviral vectors encoding brachyury protein, and their use
WO2014043535A1 (en)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Compositions for the treatment of cancer
WO2014047588A1 (en)	2012-09-21	2014-03-27	Elizabeth Mckenna	Naturally occurring cpg oligonucleotide compositions and therapeutic applications thereof
JP2016501515A (ja)	2012-10-24	2016-01-21	プレートレットターゲテッドセラピューティクス，エルエルシー	血小板標的化治療
WO2014090265A1 (en)	2012-12-13	2014-06-19	Ruprecht-Karls-Universität Heidelberg	Msi-specific frameshift peptides (fsp) for prevention and treatment of cancer
CN105025854A (zh)	2013-01-07	2015-11-04	宾夕法尼亚大学董事会	治疗皮肤t细胞淋巴瘤的组合物和方法
EP2948469A4 (en)	2013-01-23	2016-11-02	Univ Leland Stanford Junior	STABILIZED HEPATITIS B CORE POLYPEPTIDE
AU2014243756B2 (en)	2013-03-13	2018-09-27	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Prefusion RSV F proteins and their use
US10058603B2 (en)	2013-03-15	2018-08-28	Glaxosmithkline Biologicals S.A.	Vaccine
US9909114B2 (en)	2013-03-28	2018-03-06	Infectious Disease Research Institute	Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
EP3760223A1 (en)	2013-04-03	2021-01-06	N-Fold Llc	Nanoparticle composition for desensitizing a subject to peanut allergens
CN105209047B (zh)	2013-04-18	2020-08-18	免疫设计股份有限公司	用于癌症治疗的gla单一疗法
CN105392882A (zh)	2013-04-19	2016-03-09	加利福尼亚大学董事会	孤星病毒
JP2016520077A (ja)	2013-05-15	2016-07-11	ザガバナーズオブザユニバーシティオブアルバータ	Ｅ１ｅ２ｈｃｖワクチン及び使用方法
US9463198B2 (en)	2013-06-04	2016-10-11	Infectious Disease Research Institute	Compositions and methods for reducing or preventing metastasis
GB201310008D0 (en)	2013-06-05	2013-07-17	Glaxosmithkline Biolog Sa	Immunogenic composition for use in therapy
WO2014201245A1 (en)	2013-06-12	2014-12-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Tlr-9 agonist with tlr-7 and/or tlr-8 agonist for treating tumors
KR20160042917A (ko)	2013-07-25	2016-04-20	엑시큐어, 인크.	예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
EP3632458B1 (en)	2013-07-26	2025-03-19	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of bacterial infections
JP6564367B2 (ja)	2013-08-05	2019-08-21	グラクソスミスクラインバイオロジカルズソシエテアノニム	併用免疫原性組成物
SG11201510746WA (en)	2013-08-21	2016-03-30	Curevac Ag	Respiratory syncytial virus (rsv) vaccine
EP4043036A1 (en)	2013-09-27	2022-08-17	Massachusetts Institute of Technology	Carrier-free biologically-active protein nanostructures
EP3052517B1 (en)	2013-09-30	2023-07-19	Triad National Security, LLC	Mosaic conserved region hiv immunogenic polypeptides
WO2015051245A1 (en)	2013-10-04	2015-04-09	Pin Pharma, Inc.	Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment
MY182168A (en)	2013-11-01	2021-01-18	Pfizer	Vectors for expression of prostate-associated antigens
EP3063171B1 (en)	2013-11-01	2019-07-24	University Of Oslo	Albumin variants and uses thereof
US10357554B2 (en)	2013-11-11	2019-07-23	The United States Of America, As Represented By The Secretary Of The Army	AMA-1 epitopes, antibodies, compositions, and methods of making and using the same
US9993541B2 (en)	2013-11-13	2018-06-12	University Of Oslo	Outer membrane vesicles and uses thereof
US11452767B2 (en)	2013-11-15	2022-09-27	Oslo Universitetssykehus Hf	CTL peptide epitopes and antigen-specific t cells, methods for their discovery, and uses thereof
WO2015077442A2 (en)	2013-11-20	2015-05-28	La Jolla Institute For Allergy And Immunology	Grass pollen immunogens and methods and uses for immune response modulation
WO2015077434A2 (en)	2013-11-20	2015-05-28	La Jolla Institute For Allergy And Immunology	Pan pollen immunogens and methods and uses for immune response modulation
EA039037B1 (ru)	2013-11-28	2021-11-24	Бавариан Нордик А/С	Рекомбинантный поксвирус для усиления врожденного иммунного ответа у позвоночного и его применение
DK3079716T3 (da)	2013-12-13	2019-08-19	Us Health	Multiepitop-tarp-peptidvaccine og anvendelser deraf.
WO2015092710A1 (en)	2013-12-19	2015-06-25	Glaxosmithkline Biologicals, S.A.	Contralateral co-administration of vaccines
IL310015B1 (en)	2013-12-31	2025-10-01	Access To Advanced Health Inst	Single vial formulation
US10144933B2 (en)	2014-01-15	2018-12-04	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108048A1 (ja) *	2014-01-15	2017-03-23	株式会社新日本科学	抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP3095460A4 (en) *	2014-01-15	2017-08-23	Shin Nippon Biomedical Laboratories, Ltd.	Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
CN106068325B (zh)	2014-01-16	2021-07-09	波涛生命科学有限公司	手性设计
EP3096785B1 (en)	2014-01-21	2020-09-09	Pfizer Inc	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
MA39228A1 (fr)	2014-01-21	2017-06-30	Immune Design Corp	Compositions à utiliser pour le traitement d'états allergiques
US11160855B2 (en)	2014-01-21	2021-11-02	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
HRP20211288T1 (hr)	2014-01-21	2021-11-26	Pfizer Inc.	Kapsularni polisaharidi bakterije streptococcus pneumoniae i njihovi konjugati
PT3096783T (pt)	2014-01-21	2021-08-16	Pfizer	Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
US10279019B2 (en)	2014-02-11	2019-05-07	Stc.Unm	PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
TW201620927A (zh)	2014-02-24	2016-06-16	葛蘭素史密斯克藍生物品公司	Ｕｓｐａ２蛋白質構築體及其用途
WO2015131053A1 (en)	2014-02-28	2015-09-03	Alk-Abelló A/S	Polypeptides derived from phl p and methods and uses thereof for immune response modulation
EP3129050A2 (en)	2014-04-01	2017-02-15	CureVac AG	Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
WO2015164798A1 (en)	2014-04-25	2015-10-29	Tria Bioscience Corp.	Synthetic hapten carrier compositions and methods
CN107073090A (zh)	2014-04-30	2017-08-18	哈佛学院董事会	结合的疫苗装置和杀死癌细胞的方法
WO2015184272A2 (en)	2014-05-30	2015-12-03	Sanofi Pasteur Biologics Llc	Expression and conformational analysis of engineered influenza hemagglutinin
US10434064B2 (en)	2014-06-04	2019-10-08	Exicure, Inc.	Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
EP2952893A1 (en)	2014-06-04	2015-12-09	Institut d'Investigació Biomèdica de Bellvitge (IDIBELL)	Method for detecting antibody-secreting B cells specific for HLA
EP3888676A1 (en)	2014-06-13	2021-10-06	GlaxoSmithKline Biologicals S.A.	Immunogenic combinations
CA2955015A1 (en)	2014-07-15	2016-01-21	Immune Design Corp.	Prime-boost regimens with a tlr4 agonist adjuvant and a lentiviral vector
EP3169699A4 (en)	2014-07-18	2018-06-20	The University of Washington	Cancer vaccine compositions and methods of use thereof
WO2016012385A1 (en)	2014-07-21	2016-01-28	Sanofi Pasteur	Vaccine composition comprising ipv and cyclodextrins
WO2016029077A1 (en)	2014-08-22	2016-02-25	Janus Biotherapeutics, Inc.	Novel n2, n4, n7, 6-tetrasubstituted pteridine-2,4,7-triamine and 2, 4, 6, 7-tetrasubstituted pteridine compounds and methods of synthesis and use thereof
WO2016057549A1 (en)	2014-10-06	2016-04-14	Aurasense Therapeutics, Llc	Anti-tnf compounds
EP3204039B1 (en)	2014-10-10	2022-06-08	The Regents Of The University Of Michigan	Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease
AU2015252119A1 (en)	2014-11-07	2016-05-26	Takeda Vaccines, Inc.	Hand, foot, and mouth vaccines and methods of manufacture and use thereof
AR102547A1 (es)	2014-11-07	2017-03-08	Takeda Vaccines Inc	Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
EP3220895B1 (en)	2014-11-21	2022-08-31	Northwestern University	The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2016091904A1 (en)	2014-12-10	2016-06-16	Glaxosmithkline Biologicals Sa	Method of treatment
PT3233912T (pt)	2014-12-19	2021-08-09	Regenesance B V	Antocorpos que se ligam a c6 humano e utilizações destes
MX393750B (es)	2014-12-31	2025-03-24	Checkmate Pharmaceuticals Inc	Inmunoterapia antitumoral combinada.
US11352642B2 (en)	2015-01-09	2022-06-07	Etubics Corporation	Methods and compositions for combination immunotherapy
CN107427568B (zh)	2015-01-15	2021-12-14	辉瑞公司	用于肺炎球菌疫苗中的免疫原性组合物
WO2016123573A1 (en)	2015-01-30	2016-08-04	President And Fellows Of Harvard College	Peritumoral and intratumoral materials for cancer therapy
US20180036334A1 (en)	2015-02-13	2018-02-08	Icahn School Of Medicine At Mount Sinai	Rna containing compositions and methods of their use
WO2016140702A1 (en)	2015-03-03	2016-09-09	The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces	Display platform from bacterial spore coat proteins
EP4226936A3 (en)	2015-03-05	2023-09-27	Northwestern University	Non-neuroinvasive viruses and uses thereof
EP3268037B1 (en)	2015-03-09	2022-08-31	Celldex Therapeutics, Inc.	Cd27 agonists
US20180071380A1 (en)	2015-03-20	2018-03-15	The Regents Of The University Of Michigan	Immunogenic compositions for use in vaccination against bordetella
KR20240145064A (ko)	2015-03-26	2024-10-04	지피앤 백신즈 피티와이 엘티디	연쇄상구균 백신
JP7094533B2 (ja)	2015-04-10	2022-07-04	プレジデントアンドフェローズオブハーバードカレッジ	免疫細胞捕捉デバイスおよびその製造および使用方法
WO2016172249A1 (en)	2015-04-20	2016-10-27	Etubics Corporation	Methods and compositions for combination immunotherapy
WO2016180852A1 (en)	2015-05-12	2016-11-17	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods for preparing antigen-specific t cells from an umbilical cord blood sample
SG10201912485PA (en)	2015-05-13	2020-02-27	Agenus Inc	Vaccines for treatment and prevention of cancer
US10682314B2 (en)	2015-05-26	2020-06-16	Ohio State Innovation Foundation	Nanoparticle based vaccine strategy against swine influenza virus
WO2016196846A2 (en)	2015-06-02	2016-12-08	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
US10954492B2 (en)	2015-06-10	2021-03-23	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Processes for production and purification of nucleic acid-containing compositions
KR20180021874A (ko) *	2015-06-26	2018-03-05	바이엘 애니멀 헬스 게엠베하	시토졸 dna 감시 분자의 조절 방법
IL303998A (en)	2015-07-21	2023-08-01	Pfizer	Immunogenic preparations containing conjugated capsular sugar antigens, kits containing them and their uses
WO2017011918A1 (en)	2015-07-22	2017-01-26	University Of Saskatchewan	Mycoplasma bovis vaccines and uses thereof
JP6887685B2 (ja)	2015-08-12	2021-06-16	マサチューセッツインスティテュートオブテクノロジー	ナノ粒子の細胞表面共役
CA2996383A1 (en)	2015-08-25	2017-03-02	Nancy GUPTA	Immunomodulatory compositions and methods of use thereof
US11260018B2 (en)	2015-09-17	2022-03-01	Jrx Biotechnology, Inc.	Approaches for improving skin hydration and moisturization
US10526309B2 (en)	2015-10-02	2020-01-07	The University Of North Carolina At Chapel Hill	Pan-TAM inhibitors and Mer/Axl dual inhibitors
US10548970B2 (en)	2015-10-05	2020-02-04	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Human rotavirus G9P[6] strain and use as a vaccine
WO2017060857A1 (en)	2015-10-08	2017-04-13	The Governors Of The University Of Alberta	Hepatitis c virus e1/e2 heterodimers and methods of producing same
GB201518668D0 (en)	2015-10-21	2015-12-02	Glaxosmithkline Biolog Sa	Immunogenic Comosition
AU2016343845B2 (en)	2015-10-30	2023-04-13	Baylor College Of Medicine	Compositions and methods for the treatment of HER2-expressing solid tumors
EP3377098A1 (en)	2015-11-20	2018-09-26	Pfizer Inc	Immunogenic compositions for use in pneumococcal vaccines
WO2017120504A1 (en)	2016-01-08	2017-07-13	Durfee Paul N	Osteotropic nanoparticles for prevention or treatment of bone metastases
HUE059343T2 (hu)	2016-01-29	2022-11-28	Bavarian Nordic As	Rekombináns, módosított Ankara Vaccinia vírus (MVA) és ló encephalitis vírus oltóanyag
US11752238B2 (en)	2016-02-06	2023-09-12	President And Fellows Of Harvard College	Recapitulating the hematopoietic niche to reconstitute immunity
CN109562154A (zh)	2016-03-10	2019-04-02	爱普瑞希斯有限公司	带有修饰hsp70域的抗原结合融合蛋白
WO2017158421A1 (en)	2016-03-14	2017-09-21	University Of Oslo	Anti-viral engineered immunoglobulins
KR102895909B1 (ko)	2016-03-14	2025-12-05	유니버시티에트 이 오슬로	변경된 FcRn 결합을 갖는 조작된 면역글로불린
US20190046638A1 (en)	2016-04-01	2019-02-14	Checkmate Pharmaceuticals, Inc.	Fc RECEPTOR-MEDIATED DRUG DELIVERY
AU2017252527A1 (en)	2016-04-18	2018-11-08	Celldex Therapeutics, Inc.	Agonistic antibodies that bind human CD40 and uses thereof
WO2017189448A1 (en)	2016-04-25	2017-11-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bivalent immunogenic conjugate for malaria and typhoid
CA3023968A1 (en)	2016-05-16	2017-11-23	Infectious Disease Research Institute	Formulation containing tlr agonist and methods of use
WO2017201390A1 (en)	2016-05-19	2017-11-23	The Regents Of The University Of Michigan	Novel adjuvant compositions
US20200148729A1 (en)	2016-05-21	2020-05-14	Infectious Disease Research Institute	Compositions and Methods for Treating Secondary Tuberculosis and Nontuberculosis Mycobacterium Infections
EP3463440A4 (en)	2016-05-27	2020-04-15	Etubics Corporation	NEOEPITOP VACCINE COMPOSITIONS AND METHOD FOR USE THEREOF
AU2017273650B2 (en)	2016-06-01	2022-08-18	Access To Advanced Health Institute	Nanoalum particles containing a sizing agent
AU2017272344B2 (en)	2016-06-02	2022-03-03	Sanofi Pasteur Inc.	Engineered influenza antigenic polypeptides and immunogenic compositions thereof
EP3464327A1 (en)	2016-06-03	2019-04-10	Sanofi Pasteur Inc.	Modification of engineered influenza hemagglutinin polypeptides
WO2017218339A1 (en)	2016-06-13	2017-12-21	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
US11472856B2 (en)	2016-06-13	2022-10-18	Torque Therapeutics, Inc.	Methods and compositions for promoting immune cell function
GB201610599D0 (en)	2016-06-17	2016-08-03	Glaxosmithkline Biologicals Sa	Immunogenic Composition
WO2017221072A2 (en)	2016-06-21	2017-12-28	University Of Oslo	Hla binding vaccine moieties and uses thereof
WO2018009603A1 (en)	2016-07-08	2018-01-11	The United State of America, as represented by the Secretary, Department of Health and Human Service	Chimeric west nile/zika viruses and methods of use
WO2018009604A1 (en)	2016-07-08	2018-01-11	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Chimeric dengue/zika viruses live-attenuated zika virus vaccines
JP2019522486A (ja)	2016-07-13	2019-08-15	プレジデントアンドフェローズオブハーバードカレッジ	抗原提示細胞模倣足場およびそれを作製および使用するための方法
KR102638898B1 (ko)	2016-08-02	2024-02-22	프레지던트 앤드 펠로우즈 오브 하바드 칼리지	면역 반응을 조정하기 위한 생체재료
CA3031799A1 (en)	2016-08-05	2018-02-08	Sanofi Pasteur, Inc.	Multivalent pneumococcal polysaccharide-protein conjugate composition
MY199342A (en)	2016-08-05	2023-10-24	Sanofi Pasteur Inc	Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2019002178A (es)	2016-08-23	2019-09-18	Glaxosmithkline Biologicals Sa	Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
US11364304B2 (en)	2016-08-25	2022-06-21	Northwestern University	Crosslinked micellar spherical nucleic acids
CA3036218A1 (en)	2016-09-16	2018-03-22	Infectious Disease Research Institute	Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
WO2018060288A1 (en)	2016-09-29	2018-04-05	Glaxosmithkline Biologicals S.A.	Compositions and methods of treatment of persistent hpv infection
CA3039068A1 (en) *	2016-10-07	2018-04-12	Secarna Pharmaceuticals Gmbh & Co. Kg	Immunosuppression-reverting oligonucleotides inhibiting the expression of cd39
US10172933B2 (en)	2016-10-31	2019-01-08	The United States Of America, As Represented By The Secretary Of Agriculture	Mosaic vaccines for serotype a foot-and-mouth disease virus
WO2018096396A1 (en)	2016-11-22	2018-05-31	University Of Oslo	Albumin variants and uses thereof
GB201620968D0 (en)	2016-12-09	2017-01-25	Glaxosmithkline Biologicals Sa	Adenovirus polynucleotides and polypeptides
WO2018109220A2 (en)	2016-12-16	2018-06-21	Institute For Research In Biomedicine	Novel recombinant prefusion rsv f proteins and uses thereof
WO2018134693A1 (en)	2017-01-20	2018-07-26	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
US11344629B2 (en)	2017-03-01	2022-05-31	Charles Jeffrey Brinker	Active targeting of cells by monosized protocells
WO2018162450A1 (en)	2017-03-06	2018-09-13	Fundación Para La Investigación Médica Aplicada	New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
US11167022B2 (en)	2017-03-31	2021-11-09	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
WO2018178265A1 (en)	2017-03-31	2018-10-04	Glaxosmithkline Intellectual Property Development Limited	Immunogenic composition, use and method of treatment
CN118085055A (zh)	2017-04-19	2024-05-28	生物医学研究所	作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
US11696954B2 (en)	2017-04-28	2023-07-11	Exicure Operating Company	Synthesis of spherical nucleic acids using lipophilic moieties
CA3066915A1 (en)	2017-06-11	2018-12-20	Molecular Express, Inc.	Methods and compositions for substance use disorder vaccine formulations and uses thereof
ES3003260T3 (en)	2017-06-15	2025-03-10	Access To Advanced Health Inst	Nanostructured lipid carriers and stable emulsions and uses thereof
BR112020001255A2 (pt)	2017-07-21	2020-07-28	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	composições imunogênicas de neisseria meningitidis
WO2019034575A1 (en)	2017-08-14	2019-02-21	Glaxosmithkline Biologicals Sa	Methods of boosting immune responses
US11123415B2 (en)	2017-08-16	2021-09-21	Ohio State Innovation Foundation	Nanoparticle compositions for Salmonella vaccines
KR20210032924A (ko)	2017-09-05	2021-03-25	토크 테라퓨틱스, 인코포레이티드	치료용 단백질 조성물 및 그의 제조 및 사용 방법
EP3678698A1 (en)	2017-09-07	2020-07-15	University Of Oslo	Vaccine molecules
WO2019048936A1 (en)	2017-09-07	2019-03-14	University Of Oslo	VACCINE MOLECULES
KR102755593B1 (ko)	2017-09-08	2025-01-20	액세스 투 어드밴스드 헬스 인스티튜트	사포닌을 포함하는 리포솜 제형 및 사용 방법
AU2018330495A1 (en)	2017-09-08	2020-03-26	Mina Therapeutics Limited	Stabilized hnf4a sarna compositions and methods of use
CN111556757A (zh)	2017-10-31	2020-08-18	西方溶瘤细胞有限公司	用于全身递送的平台溶瘤载体
CA3081586A1 (en)	2017-11-03	2019-05-09	Takeda Vaccines, Inc.	Zika vaccines and immunogenic compositions, and methods of using the same
EP3703745B1 (en)	2017-11-04	2024-04-10	Nevada Research & Innovation Corporation	Immunogenic conjugates and methods of use thereof
MX2020006243A (es) *	2017-12-15	2020-09-03	Bayer Animal Health Gmbh	Oligonucleotidos inmunoestimulantes.
US11116830B2 (en)	2017-12-18	2021-09-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Bacterial polysaccharide-conjugated carrier proteins and use thereof
CN111741767A (zh)	2017-12-19	2020-10-02	麻省理工学院	抗原-佐剂偶联剂和使用方法
GB201721582D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	S aureus antigens and immunogenic compositions
GB201721576D0 (en)	2017-12-21	2018-02-07	Glaxosmithkline Biologicals Sa	Hla antigens and glycoconjugates thereof
EP3743107A1 (en)	2018-01-22	2020-12-02	The United States of America, as represented by the Secretary, Department of Health and Human Services	Broadly protective inactivated influenza virus vaccine
WO2019147925A1 (en)	2018-01-26	2019-08-01	Nantcell, Inc.	Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
KR102812816B1 (ko)	2018-02-05	2025-05-27	사노피 파스퇴르 인코포레이티드	다가 폐렴구균성 다당류-단백질 접합체 조성물
EP3752194A4 (en)	2018-02-13	2022-03-16	Checkmate Pharmaceuticals, Inc.	COMPOSITIONS AND METHODS FOR TUMOR IMMUNOTHERAPY
US11492377B2 (en)	2018-02-16	2022-11-08	2A Pharma Ab	Parvovirus structural protein for the treatment of autoimmune diseases
EP3527223A1 (en)	2018-02-16	2019-08-21	2A Pharma AB	Mutated parvovirus structural protein
CA3034912A1 (en)	2018-02-28	2019-08-28	Pfizer Inc.	Il-15 variants and uses thereof
WO2019173438A1 (en)	2018-03-06	2019-09-12	Stc. Unm	Compositions and methods for reducing serum triglycerides
CN112189019B (zh)	2018-03-28	2024-10-25	圣诺菲·帕斯图尔公司	产生包含血凝素的广泛保护性疫苗组合物的方法
WO2019195291A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic respiratory syncytial virus polypeptides
CN112512564A (zh)	2018-04-03	2021-03-16	赛诺菲	铁蛋白蛋白
EP3773703A1 (en)	2018-04-03	2021-02-17	Sanofi	Antigenic influenza-ferritin polypeptides
WO2019195276A1 (en)	2018-04-03	2019-10-10	Sanofi	Antigenic ospa polypeptides
JP7614842B2 (ja)	2018-04-03	2025-01-16	サノフイ	抗原性エプスタインバーウイルスポリペプチド
KR102890791B1 (ko)	2018-04-09	2025-11-24	체크메이트 파마슈티칼스, 인크.	바이러스-유사 입자 내로의 올리고뉴클레오타이드의 포장
WO2019204462A2 (en)	2018-04-17	2019-10-24	Celldex Therapeutics, Inc.	Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
US11525010B2 (en)	2018-05-23	2022-12-13	Pfizer Inc.	Antibodies specific for GUCY2c and uses thereof
BR112020022897A2 (pt)	2018-05-23	2021-02-23	Pfizer Inc.	anticorpos específicos para cd3 e usos dos mesmos
WO2019239311A1 (en)	2018-06-12	2019-12-19	Glaxosmithkline Biologicals Sa	Adenovirus polynucleotides and polypeptides
EP3820511A4 (en)	2018-07-13	2022-06-15	University of Georgia Research Foundation, Inc.	INFLUENZA H3 VIRUS WIDELY REACTIVE IMMUNOGENS, COMPOSITIONS AND METHODS OF USE THE SAME
BR112021000529A2 (pt)	2018-07-19	2021-04-06	Glaxosmithkline Biologicals S.A.	Processos para preparar polissacarídeos secos
WO2020030572A1 (en)	2018-08-07	2020-02-13	Glaxosmithkline Biologicals Sa	Processes and vaccines
US11260119B2 (en)	2018-08-24	2022-03-01	Pfizer Inc.	Escherichia coli compositions and methods thereof
CN111315407B (zh)	2018-09-11	2023-05-02	上海市公共卫生临床中心	一种广谱抗流感疫苗免疫原及其应用
WO2020061129A1 (en)	2018-09-19	2020-03-26	President And Fellows Of Harvard College	Compositions and methods for labeling and modulation of cells in vitro and in vivo
WO2020068798A1 (en)	2018-09-24	2020-04-02	Guo Jimin	Living mammalian cells modified with functional modular nanoparticles
CN119241692A (zh)	2018-12-04	2025-01-03	洛克菲勒大学	Hiv疫苗免疫原
EP3890775A1 (en)	2018-12-06	2021-10-13	GlaxoSmithKline Biologicals S.A.	Immunogenic compositions
EP3894431A2 (en)	2018-12-12	2021-10-20	GlaxoSmithKline Biologicals SA	Modified carrier proteins for o-linked glycosylation
WO2020123777A1 (en)	2018-12-12	2020-06-18	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Recombinant mumps virus vaccine expressing genotype g fusion and hemagglutinin-neuraminidase proteins
US20220016229A1 (en)	2018-12-12	2022-01-20	Pfizer Inc.	Immunogenic Multiple Hetero-Antigen Polysaccharide-Protein Conjugates and uses thereof
WO2020123989A1 (en)	2018-12-14	2020-06-18	University Of Georgia Research Foundation, Inc.	Crimean-congo hemorrhagic fever virus replicon particles and use thereof
EP3897846A1 (en)	2018-12-21	2021-10-27	GlaxoSmithKline Biologicals SA	Methods of inducing an immune response
WO2020128893A1 (en)	2018-12-21	2020-06-25	Pfizer Inc.	Combination treatments of cancer comprising a tlr agonist
GB201901608D0 (en)	2019-02-06	2019-03-27	Vib Vzw	Vaccine adjuvant conjugates
US12208164B2 (en)	2019-02-28	2025-01-28	Unm Rainforest Innovations	Modular metal-organic polyhedra superassembly compositions
WO2020205986A1 (en)	2019-04-02	2020-10-08	Sanofi	Antigenic multimeric respiratory syncytial virus polypeptides
CA3136278A1 (en)	2019-04-10	2020-10-15	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
US20220221455A1 (en)	2019-04-18	2022-07-14	Glaxosmithkline Biologicals Sa	Antigen binding proteins and assays
GB2598494B (en)	2019-05-20	2024-07-24	Valneva Se	A subunit vaccine for treatment or prevention of a respiratory tract infection
MX2021014363A (es)	2019-05-25	2022-02-21	Infectious Disease Res Inst	Composicion y metodo para secar por pulverizacion una emulsion de vacuna adyuvante.
WO2020240268A1 (en)	2019-05-31	2020-12-03	Universidad De Chile	An immunogenic formulation that induces protection against shiga toxin-producing escherichia coli (stec)
EP3770269A1 (en)	2019-07-23	2021-01-27	GlaxoSmithKline Biologicals S.A.	Quantification of bioconjugate glycosylation
CA3148924A1 (en)	2019-08-05	2021-02-11	Glaxosmithkline Biologicals Sa	Immunogenic composition
EP4021894A1 (en)	2019-08-30	2022-07-06	University of Rochester	Septin inhibitors for treatment of cancers
EP4438053A3 (en)	2019-09-18	2025-03-05	Children's Medical Center Corporation	An anaplastic lymphoma kinase (alk) cancer vaccine and methods of use
EP3799884A1 (en)	2019-10-01	2021-04-07	GlaxoSmithKline Biologicals S.A.	Immunogenic compositions
MX2022005252A (es)	2019-11-01	2022-06-08	Pfizer	Composiciones de escherichia coli y metodos de las mismas.
EP4058581A1 (en)	2019-11-15	2022-09-21	Infectious Disease Research Institute	Rig-i agonist and adjuvant formulation for tumor treatment
JP2023503086A (ja)	2019-11-22	2023-01-26	グラクソスミスクラインバイオロジカルズソシエテアノニム	細菌サッカリド複合糖質ワクチンの用法及び用量
WO2021127271A1 (en)	2019-12-17	2021-06-24	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Live attenuated leishmania parasite vaccines with enhanced safety characteristics
US11702474B2 (en)	2019-12-17	2023-07-18	Pfizer Inc.	Antibodies specific for CD47, PD-L1, and uses thereof
IL295632A (en)	2020-02-23	2022-10-01	Pfizer	Escherichia coli preparations and their methods
EP4110382A1 (en)	2020-02-28	2023-01-04	Sanofi Pasteur Inc.	High dose influenza vaccine for pediatric subjects
US11213482B1 (en)	2020-03-05	2022-01-04	University of Pittsburgh—Of the Commonwealth System of Higher Educat	SARS-CoV-2 subunit vaccine and microneedle array delivery system
AU2021258911A1 (en)	2020-04-20	2022-11-24	The University Of British Columbia	Compositions and methods for preventing, controlling and diagnosing mycobacterial infections
JP2023533793A (ja)	2020-07-17	2023-08-04	ファイザー・インク	治療用抗体およびそれらの使用
CA3174411A1 (en)	2020-09-04	2022-03-10	Ryan M. Kramer	Co-lyophilized rna and nanostructured lipid carrier
WO2022066973A1 (en)	2020-09-24	2022-03-31	Fred Hutchinson Cancer Research Center	Immunotherapy targeting pbk or oip5 antigens
EP4217387A2 (en)	2020-09-24	2023-08-02	Fred Hutchinson Cancer Center	Immunotherapy targeting sox2 antigens
CA3194598A1 (en)	2020-10-07	2022-04-14	Valentina SCREPANTI-SUNDQUIST	Cholera vaccine formulation
WO2022083760A1 (zh)	2020-10-23	2022-04-28	江苏省疾病预防控制中心(江苏省公共卫生研究院)	融合蛋白及其应用
US12138302B2 (en)	2020-10-27	2024-11-12	Pfizer Inc.	Escherichia coli compositions and methods thereof
EP4237428A2 (en)	2020-10-27	2023-09-06	Pfizer Inc.	Escherichia coli compositions and methods thereof
US20240000912A1 (en)	2020-11-04	2024-01-04	Pfizer Inc.	Immunogenic compositions for use in pneumococcal vaccines
EP4243863A2 (en)	2020-11-10	2023-09-20	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
EP4247410A4 (en)	2020-11-19	2025-05-07	KaliVir Immunotherapeutics, Inc.	ONCOLYTIC IMMUNOTHERAPY BY TUMOR MICROENVIRONMENT REMOVAL
US12357681B2 (en)	2020-12-23	2025-07-15	Pfizer Inc.	E. coli FimH mutants and uses thereof
AU2021406131A1 (en)	2020-12-23	2023-08-03	Access To Advanced Health Institute	Solanesol vaccine adjuvants and methods of preparing same
US20240299510A1 (en)	2020-12-31	2024-09-12	The United States Of America,As Represented By The Secretary,Department Of Health And Human Services	Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
JP2024510717A (ja)	2021-02-22	2024-03-11	グラクソスミスクラインバイオロジカルズソシエテアノニム	免疫原性組成物、使用及び方法
WO2022207793A1 (en)	2021-03-31	2022-10-06	Vib Vzw	Vaccine compositions for trypanosomatids
BR112023020303A2 (pt)	2021-04-09	2023-11-14	Celldex Therapeutics Inc	Anticorpos contra ilt4, anticorpo anti-ilt4/pd-l1 bispecífico e seus usos
CN117279659A (zh)	2021-04-09	2023-12-22	瓦尔尼瓦公司	人偏肺病毒疫苗
BR112023022681A2 (pt)	2021-04-30	2024-01-23	Kalivir Immunotherapeutics Inc	Vírus oncolíticos para expressão modificada de mhc
JP2024521847A (ja)	2021-05-28	2024-06-04	ファイザー・インク	コンジュゲート化莢膜糖抗原を含む免疫原性組成物およびその使用
CA3221074A1 (en)	2021-05-28	2022-12-01	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3226187A1 (en)	2021-07-16	2023-01-19	The Board Of Trustees Of The University Of Illinois	Universal vaccine for influenza virus based on tetrameric m2 protein incorporated into nanodiscs
JP2024532763A (ja)	2021-08-11	2024-09-10	サノフィパスツールインコーポレイテッド	切断型インフルエンザノイラミニダーゼおよびこれを使用する方法
EP4412647A1 (en)	2021-10-08	2024-08-14	Sanofi Pasteur, Inc.	Multivalent influenza vaccines
CA3237139A1 (en)	2021-11-05	2023-05-11	Sanofi	Hybrid multivalent influenza vaccines comprising hemagglutinin and neuraminidase and methods of using the same
JP2024542085A (ja)	2021-11-05	2024-11-13	サノフイ	呼吸器合胞体ウイルスｒｎａワクチン
CN118201635A (zh)	2021-11-05	2024-06-14	圣诺菲·帕斯图尔公司	包含重组血凝素和神经氨酸酶的多价流感疫苗及其使用方法
WO2023077521A1 (en)	2021-11-08	2023-05-11	Celldex Therapeutics, Inc	Anti-ilt4 and anti-pd-1 bispecific constructs
WO2023083964A1 (en)	2021-11-11	2023-05-19	2A Pharma Ab	Parvovirus structural protein against beta- and gamma-hpv
AU2022399571A1 (en)	2021-11-30	2024-07-11	Sanofi Pasteur Inc.	Human metapneumovirus vaccines
WO2023102388A1 (en)	2021-11-30	2023-06-08	Sanofi Pasteur Inc.	Human metapneumovirus viral vector-based vaccines
EP4448548B8 (en)	2021-12-13	2025-12-03	The United States of America, as represented by The Secretary, Department of Health and Human Services	Bacteriophage lambda-vaccine system
CA3242439A1 (en)	2021-12-17	2023-06-22	Sanofi	Lyme disease rna vaccine
JP2025508749A (ja)	2022-01-13	2025-04-10	ファイザー・インク	コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
EP4469565A1 (en)	2022-01-27	2024-12-04	Sanofi Pasteur	Modified vero cells and methods of using the same for virus production
WO2023161817A1 (en)	2022-02-25	2023-08-31	Pfizer Inc.	Methods for incorporating azido groups in bacterial capsular polysaccharides
EP4494148A1 (en)	2022-03-14	2025-01-22	Sanofi Pasteur Inc.	Machine-learning techniques in protein design for vaccine generation
AU2023265481A1 (en)	2022-05-06	2024-12-19	Sanofi	Signal sequences for nucleic acid vaccines
CA3256617A1 (en)	2022-05-11	2023-11-16	Pfizer Inc.	PROCESS FOR PRODUCING VACCINE FORMULATIONS WITH PRESERVATIVES
EP4531899A1 (en)	2022-06-01	2025-04-09	Valneva Austria GmbH	Clostridium difficile vaccine
CN119630419A (zh)	2022-06-29	2025-03-14	巴法里安诺迪克有限公司	重组修饰的saRNA(VRP)和痘苗病毒安卡拉(MVA)初免-加强方案
CA3266697A1 (en)	2022-09-09	2024-03-14	Access To Advanced Health Institute	COMPOSITION OF AN IMMUNOGENEOUS VACCINE CONTAINING A SAPONIN
AU2023374764A1 (en)	2022-11-04	2025-06-19	Sanofi Pasteur Inc.	Respiratory syncytial virus rna vaccination
WO2024110827A1 (en)	2022-11-21	2024-05-30	Pfizer Inc.	Methods for preparing conjugated capsular saccharide antigens and uses thereof
PE20251701A1 (es)	2022-11-22	2025-07-02	Pfizer	Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos
KR20250113501A (ko)	2022-12-01	2025-07-25	화이자 인코포레이티드	폐렴구균 접합체 백신 제형
WO2024121380A1 (en)	2022-12-08	2024-06-13	Pierre Fabre Medicament	Vaccinal composition and adjuvant
JP2025541207A (ja)	2022-12-13	2025-12-18	ファイザー・インク	クロストリディオイデス（クロストリジウム）・ディフィシル（ｃｌｏｓｔｒｉｄｉｏｉｄｅｓ（ｃｌｏｓｔｒｉｄｉｕｍ）ｄｉｆｆｉｃｉｌｅ）に対する免疫応答を誘発するための免疫原性組成物および方法
CN120475991A (zh)	2022-12-20	2025-08-12	赛诺菲巴斯德有限公司	鼻病毒mRNA疫苗
WO2024149832A1 (en)	2023-01-12	2024-07-18	Bavarian Nordic A/S	RECOMBINANT MODIFIED saRNA (VRP) FOR CANCER VACCINE
WO2024163327A1 (en)	2023-01-30	2024-08-08	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Epstein-barr virus glycoprotein 42 immunogens for vaccination and antibody discovery
EP4661911A1 (en)	2023-02-10	2025-12-17	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN120813371A (zh)	2023-03-02	2025-10-17	赛诺菲巴斯德有限公司	用于在衣原体病的治疗中使用的组合物
CN121219315A (zh)	2023-03-03	2025-12-26	塞德斯医疗公司	抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
WO2024201324A2 (en)	2023-03-30	2024-10-03	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
AU2024255922A1 (en)	2023-04-14	2025-10-30	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024224266A1 (en)	2023-04-24	2024-10-31	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
TW202500750A (zh)	2023-05-05	2025-01-01	法商賽諾菲公司	用於治療痤瘡的組成物
TW202508620A (zh)	2023-05-10	2025-03-01	尼可拉斯克拉克	呼吸道mrna組合疫苗
US20240398932A1 (en)	2023-05-11	2024-12-05	Sanofi Pasteur Inc.	Respiratory syncytial virus vaccine and methods of use
WO2024241172A2 (en)	2023-05-19	2024-11-28	Glaxosmithkline Biologicals Sa	Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
WO2024246358A1 (en)	2023-06-01	2024-12-05	Sanofi	Thermostable compositions comprising mrna lipid nanoparticles
WO2025006737A1 (en)	2023-06-30	2025-01-02	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Genetically detoxified mutant of neisseria and outer membrane vesicle (omv) vaccine
WO2025017202A2 (en)	2023-07-19	2025-01-23	Sanofi	Porphyromonas gingivalis antigenic constructs
US20250090650A1 (en)	2023-09-06	2025-03-20	Sanofi	Modified influenza b hemagglutinin polypeptides and nucleic acids and uses thereof
WO2025057078A1 (en)	2023-09-14	2025-03-20	Pfizer Inc.	Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
TW202535439A (zh)	2023-11-17	2025-09-16	美商賽諾菲巴斯德公司	海藻糖疫苗調配物
WO2025133971A1 (en)	2023-12-23	2025-06-26	Pfizer Inc.	Improved methods for producing bacterial capsular saccharide glycoconjugates
WO2025163460A2 (en)	2024-01-30	2025-08-07	Pfizer Inc.	Vaccines against respiratory diseases
WO2025186705A2 (en)	2024-03-06	2025-09-12	Pfizer Inc.	Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US20250281605A1 (en)	2024-03-08	2025-09-11	Sanofi	Antigenic Epstein Barr Virus Polypeptides
WO2025191415A1 (en)	2024-03-11	2025-09-18	Pfizer Inc.	Immunogenic compositions comprising conjugated escherichia coli saccharides and uses thereof
WO2025210592A1 (en)	2024-04-05	2025-10-09	Sanofi Pasteur Inc.	Muscle cell lnp-mrna quality control assays
WO2025219904A1 (en)	2024-04-19	2025-10-23	Pfizer Inc.	Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
WO2025238502A1 (en)	2024-05-14	2025-11-20	Pfizer Inc.	Aluminum adjuvant nanoparticles, methods of manufacture, and uses thereof
WO2025257712A1 (en)	2024-06-12	2025-12-18	Pfizer Inc.	Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2034118A1 (en) †	1970-07-09	1972-01-13	Seinfeld, Hugo, Brendel, Walter, Prof Dr . 8000 München	Xenogenic nucleic acids for enhancing antigenicity - of peptides and proteins
US4956296A (en) *	1987-06-19	1990-09-11	Genex Corporation	Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
US5059519A (en) *	1986-07-01	1991-10-22	University Of Massachusetts Medical School	Oligonucleotide probes for the determination of the proclivity for development of autoimmune diseases
CA1339596C (en)	1987-08-07	1997-12-23	New England Medical Center Hospitals, Inc.	Viral expression inhibitors
US5786189A (en) *	1989-11-29	1998-07-28	Smithkline Beecham Biologicals (S.A.)	Vaccine
US5248670A (en)	1990-02-26	1993-09-28	Isis Pharmaceuticals, Inc.	Antisense oligonucleotides for inhibiting herpesviruses
EP0468520A3 (en) *	1990-07-27	1992-07-01	Mitsui Toatsu Chemicals, Inc.	Immunostimulatory remedies containing palindromic dna sequences
JPH04352724A (ja) *	1990-07-27	1992-12-07	Mitsui Toatsu Chem Inc	免疫調節型治療剤
ATE154947T1 (de)	1990-08-16	1997-07-15	Isis Pharmaceuticals Inc	Oligonukleotide zur modulation der effekte von cytomegalovirusinfektionen
US5234811A (en) *	1991-09-27	1993-08-10	The Scripps Research Institute	Assay for a new gaucher disease mutation
WO1993010138A1 (en) *	1991-11-18	1993-05-27	Tanox Biosystems, Inc.	Anti-sense oligonucleotides for isotype-specific suppression of immunoglobulin production
ES2095657T3 (es)	1992-07-24	1997-02-16	Kumiai Chemical Industry Co	Derivado de triazol, procedimiento de obtencion del mismo, un agente de control de plagas y metodo de control de plagas.
US5585479A (en) *	1992-07-24	1996-12-17	The United States Of America As Represented By The Secretary Of The Navy	Antisense oligonucleotides directed against human ELAM-I RNA
EP0652890B1 (en) †	1992-07-27	1998-01-14	HYBRIDON, Inc.	Oligonucleotide alkylphosphonothioates
WO1994029461A1 (en) *	1993-06-11	1994-12-22	Commonwealth Scientific And Industrial Research Organisation	Method for specific silencing of genes by dna methylation
WO1995026204A1 (en)	1994-03-25	1995-10-05	Isis Pharmaceuticals, Inc.	Immune stimulation by phosphorothioate oligonucleotide analogs
JP3468773B2 (ja) *	1994-07-15	2003-11-17	ザユニバーシティオブアイオワリサーチファウンデーション	免疫調節オリゴヌクレオチド
US5629052A (en)	1995-02-15	1997-05-13	The Procter & Gamble Company	Method of applying a curable resin to a substrate for use in papermaking

1995
- 1995-02-07 JP JP50499196A patent/JP3468773B2/ja not_active Expired - Lifetime
- 1995-02-07 WO PCT/US1995/001570 patent/WO1996002555A1/en not_active Ceased
- 1995-02-07 ES ES95911630T patent/ES2267100T5/es not_active Expired - Lifetime
- 1995-02-07 US US08/386,063 patent/US6194388B1/en not_active Expired - Lifetime
- 1995-02-07 CA CA002560114A patent/CA2560114A1/en not_active Abandoned
- 1995-02-07 EP EP95911630A patent/EP0772619B2/en not_active Expired - Lifetime
- 1995-02-07 DE DE69535905T patent/DE69535905D1/de not_active Expired - Lifetime
- 1995-02-07 DE DE69535036T patent/DE69535036T3/de not_active Expired - Lifetime
- 1995-02-07 EP EP01202813A patent/EP1167378B1/en not_active Expired - Lifetime
- 1995-02-07 EP EP01202814A patent/EP1167379A3/en not_active Ceased
- 1995-02-07 EP EP01202811A patent/EP1167377B2/en not_active Expired - Lifetime
- 1995-02-07 ES ES01202811T patent/ES2320315T5/es not_active Expired - Lifetime
- 1995-02-07 ES ES01202813T patent/ES2366201T3/es not_active Expired - Lifetime
- 1995-02-07 AT AT01202813T patent/ATE509102T1/de not_active IP Right Cessation
- 1995-02-07 AT AT01202811T patent/ATE420171T1/de not_active IP Right Cessation
- 1995-02-07 AU AU19127/95A patent/AU713040B2/en not_active Expired
- 1995-02-07 CA CA002194761A patent/CA2194761C/en not_active Expired - Lifetime
- 1995-02-07 AT AT95911630T patent/ATE328890T1/de active
- 1995-02-07 DK DK95911630.2T patent/DK0772619T4/da active
- 1995-02-07 PT PT95911630T patent/PT772619E/pt unknown
2002
- 2002-05-13 HK HK02103584.4A patent/HK1043598A1/en unknown
- 2002-06-26 HK HK02104746.7A patent/HK1044949B/en not_active IP Right Cessation
- 2002-06-26 HK HK02104747.6A patent/HK1044950A1/en not_active IP Right Cessation
- 2002-10-16 JP JP2002302338A patent/JP2003144184A/ja not_active Withdrawn
2003
- 2003-06-23 JP JP2003178740A patent/JP2004024261A/ja not_active Withdrawn
- 2003-06-23 JP JP2003178741A patent/JP4126252B2/ja not_active Expired - Lifetime
2004
- 2004-03-11 JP JP2004069838A patent/JP2004215670A/ja not_active Withdrawn
2008
- 2008-01-25 JP JP2008015654A patent/JP2008169216A/ja not_active Withdrawn
2009
- 2009-03-10 JP JP2009057160A patent/JP2009148296A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
US6194388B1 (en)	2001-02-27
HK1044950A1 (en)	2002-11-08
DE69535036T3 (de)	2011-07-07
HK1044949B (en)	2012-01-27
ATE420171T1 (de)	2009-01-15
DE69535905D1 (de)	2009-02-26
EP1167377B1 (en)	2009-01-07
JP2004024261A (ja)	2004-01-29
ATE328890T1 (de)	2006-06-15
EP1167379A3 (en)	2004-09-08
DK0772619T3 (da)	2006-10-09
ES2366201T3 (es)	2011-10-18
EP0772619B2 (en)	2010-12-08
ES2267100T5 (es)	2011-04-08
JP2008169216A (ja)	2008-07-24
ES2320315T5 (es)	2012-12-05
WO1996002555A1 (en)	1996-02-01
AU713040B2 (en)	1999-11-18
JPH10506265A (ja)	1998-06-23
EP1167377B2 (en)	2012-08-08
DE69535036T2 (de)	2007-01-18
ATE509102T1 (de)	2011-05-15
PT772619E (pt)	2006-10-31
CA2194761A1 (en)	1996-02-01
JP2004043466A (ja)	2004-02-12
EP1167377A2 (en)	2002-01-02
EP1167379A2 (en)	2002-01-02
EP1167378A3 (en)	2005-08-17
EP0772619B1 (en)	2006-06-07
JP2009148296A (ja)	2009-07-09
HK1044949A1 (en)	2002-11-08
CA2194761C (en)	2006-12-19
JP2003144184A (ja)	2003-05-20
HK1043598A1 (en)	2002-09-20
EP1167377A3 (en)	2004-09-08
EP1167378B1 (en)	2011-05-11
EP0772619A1 (en)	1997-05-14
JP2004215670A (ja)	2004-08-05
AU1912795A (en)	1996-02-16
JP3468773B2 (ja)	2003-11-17
DE69535036D1 (de)	2006-07-20
ES2267100T3 (es)	2007-03-01
ES2320315T3 (es)	2009-05-21
EP1167378A2 (en)	2002-01-02
CA2560114A1 (en)	1996-02-01
JP4126252B2 (ja)	2008-07-30

Publication	Publication Date	Title
DE69535905D1 (de)	2009-02-26	Immunomodulatorische Oligonukleotide
DE69727183D1 (de)	2004-02-19	Angetriebenes Handstück
ZA9811848B (en)	2000-06-26	Vaccine.
ZA984969B (en)	1999-12-09	Vaccine.
ZA9811585B (en)	2000-06-19	Medical device.
EP1733735A3 (en)	2008-08-27	Methods and products for inducing mucosal immunity
ZA9711545B (en)	1998-06-24	Air treatment device.
IT1292837B1 (it)	1999-02-11	Apparecchio chirurgico per biopsia.
HUP0004453A3 (en)	2004-05-28	Sterile drape
DZ2283A1 (fr)	2002-12-25	Composition de vaccin.
ZA96722B (en)	1996-08-26	Combination therapy for hiv infection
ZA9710606B (en)	1998-06-12	Non-virulent Mycoplasma synoviae vaccine thereof.
FR2715304B1 (fr)	1996-04-26	Vaccin anti-allergique.
FI965196A7 (fi)	1996-12-23	HIV-infektion yhdistelmähoito
ZA9810445B (en)	1999-07-01	Novel bone surgical device.
ES1027473Y (es)	1995-02-16	Boton quirurgico de traccion ortodoncia.
ITBO930113V0 (it)	1993-05-19	supporto per strumenti odontoiatrici accessori.
ES1028663Y (es)	1995-07-01	Depresor lingual.
GB9610192D0 (en)	1996-07-24	DNA vaccine formulations
ES1025872Y (es)	1994-09-01	Maquina de traccion cervical.
ITMI942190A0 (it)	1994-10-26	Dispositivo di trattenimento del chiodo per martelli
ZA956662B (en)	1996-03-25	Combination therapy for HIV infection
ITMI981384A1 (it)	1999-12-18	Vaccino per hiv
IT1274909B (it)	1997-07-25	Manipolo endoorale per riprese di video-immagini.
IT1268344B1 (it)	1997-02-27	Apparecchio ortodontico distalizzatore.